Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
 
A Phase III, Double -blind, Randomized, Crossover Study of Plerixafor V ersus G -CSF in 
the Treatment of Patients with WHIM Syndrome  
 
 
 
Protocol Number:    14-I-0185  
Version Description:                       Version 6.0 
Version Date:                                 January 9 , 201 9 
Abbreviated Title:                          Plerixafor  vs. G-CSF in WHIMS 
Location of the Study:   NIH Clinical Center  
Total Subjects to be accrue d:         30 
Proposed Period :                            6 years 
  
IND:     118767  
Name of Agent:    plerixafor  and G -CSF  
Holder:     OCRPRO , DCR, NIAID  
    
 
 
USponsored by  
Office of Clinical Research Policy and Regulatory Operations (OCRPRO) 
Division of Clinical Research (DCR), Office of the Director  
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health ( NIH)  
 
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 2 of 74 
 
 STUDY STAFF ROSTER  
 
Principal Investigator:   David H. McDermott, MD 
Laboratory of Molecular Immunology ( LMI)/NIAID 
 Phone: 301-496 -8483  
E-mail: DMCDERMOTT@niaid.nih.gov   
 
Associate Investigators:   Philip M. Murphy, MD      
LMI/NIAID    
Phone: 301-496 -8616  
 
Harry L. Malech, MD       
 Laboratory of Host Defenses (LHD)/NIAID  
     Phone: 301-480 -6916  
     
Elizabeth Kang, MD       
 Laboratory of Host Defenses (LHD)/NIAID  
     Phone: 301-402 -7567  
 
Research Contact/Study  
Coordinator(s):    Daniel Velez, RN    
LMI/NIAID    
Phone: 301-594 -1549  
      Elena Cho, RN  
     LMI/NIAID 
     Phone: 301-761 -7280  
 
Statistician:     Dean Follmann, PhD 
     Biostatistics Research Branch/ DCR/NIAID  
     Phone: 301-451 -5128  
 
NIH Pharmacy  (NIH) :   Michael Kolf  
     NIH Pharmacy /NIH/Clinical Center  
     Phone: 301-496 -1031  
 Sponsor Medical Monitor :  Marc Teitelbaum , MD  
Leidos Biomedical Research, Inc.  
5705 Industry Lane  
Frederick, MD 21704  
Tel: 301 -228-4707   
Email: 
40TMarc.Teitelbaum@fnlcr.nih.gov 40T 
 
Institutional Review Board:  NIAID IRB  
  
   
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 3 of 74 
 
  Consultants:     
    Melissa Meridith, MD 
    Gynecology, NHGRI  
    301-402 -1816  
     Edward Cowen, MD  
     Dermatology , NCI 
  301-496 -4299  
   John DiGiovanna , MD   
  Dermatology, NCI  
  301-402 -1607  
 
Jeffrey H. Kim, MD  
     ENT, NIDCD 
  301-496 -4299  
 
    Carmen Brewer, PhD  
     Audiology, NIDCD 
  301-496 -5294  
 
    Katherine Calvo, MD  
     Hematologic Pathology , DLM/CC  
  301-594 -9578  
 
Pamela Gardner, DDS  
     Dentistry, NIDCR  
  301-443 -8010  
      
     Thomas Fleisher, MD  
     Clinical Immunology, DLM /CC 
     301-496 -5568  
      Alison McBride, PhD 
     Virology, LVD /NIAID  
     301-496 -1370  
      Chris Buck, PhD 
     Virology, LCO /NCI 
     301-594 -7060  
 
  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 4 of 74 
 
 TABLE OF CONTENTS  
40TSTUDY STAFF ROSTER 40T ............................................................................................................. 2  
40TTABLE OF CONTENTS 40T .............................................................................................................. 4  
40TLIST OF TABLES 40T ....................................................................................................................... 12  
40TLIST OF FIGURE S 40T ..................................................................................................................... 12  
40TLIST OF ABBREVIATIONS 40T ...................................................................................................... 13  
40TPROTOCOL SUMMARY 40T ........................................................................................................... 15  
40TPRÉCIS 40T ........................................................................................................................................ 17  
40TSTUDY SCHEMA 40T ...................................................................................................................... 18  
40T1 40T 40TBACKGROUND INF ORMATION AND SCIENTI FIC RATIONALE 40T .................... 19  
40T1.1 40T 40TBackground Information 40T .............................................................................................. 19  
40T1.1.1 40T 40TCXCR4 40T ................................................................................................................................. 19 
40T1.1.2 40T 40TWHIMS 40T ................................................................................................................................ 19 
40T1.2 40T 40TDescription of Study Agent: Mozobil™ (plerixafor) 40T ................................................... 20  
40T1.2.1 40T 40TSummary of Previous Pre -Clinical Studies 40T .......................................................................... 21 
40T1.2.2 40T 40TSummary of Relevant Clinical Studies 40T ................................................................................ 22 
40T1.3 40T 40TDescription of Comparator Treatment: G -CSF 40T ............................................................ 22  
40T1.3.1 40T 40TSummary of Relevant Clinical Studies 40T ................................................................................ 22 
40T1.4 40T 40TScientific Rationale and Clinical Justification 40T ............................................................. 23  
40T1.5 40T 40TPreliminary Report of Unexpected Adverse Events in this Study 40T ............................... 24  
40T1.5.1 40T 40TAn Incident of a New Psoriasis-like Rash 40T ........................................................................... 24 
40T1.5.2 40T 40TJoint Pain (Arthralgia) and an Incident of Reactive Arthritis 40T .............................................. 24 
40T2 40T 40TSTUDY OBJECTIVES 40T ................................................................................................ 26  
40T2.1 40T 40TPrimary Objective 40T ........................................................................................................ 26  
40T2.2 40T 40TSecondary Objectives 40T ................................................................................................... 26  
40T2.3 40T 40TExploratory Objectives 40T ................................................................................................. 26  
40T3 40T 40TSTUDY DESIGN 40T ......................................................................................................... 26  
40T3.1 40T 40TDescription of the Study Design 40T .................................................................................. 26  
40T3.2 40T 40TStudy Endpoints 40T ........................................................................................................... 27  
40T3.2.1 40T 40TPrimary Endpoint 40T ................................................................................................................. 27 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 5 of 74 
 
 40T3.2.2 40T 40TSecondary Endpoints 40T ........................................................................................................... 27 
40T3.2.3 40T 40TExploratory Endpoint 40T ........................................................................................................... 27 
40T4 40T 40TSTUDY POPULATION 40T .............................................................................................. 27  
40T4.1 40T 40TSubject Selection and Recruitment Plan 40T ...................................................................... 27  
40T4.2 40T 40TInclusion Criteria 40T .......................................................................................................... 27  
40T4.3 40T 40TExclusion Criteria 40T ......................................................................................................... 28  
40T4.4 40T 40TJustification for Exclusion of Pregnant or Breast Feeding Women 40T ............................. 28  
40T4.5 40T 40TJustification for Exclusion of Children <10 Years of Age 40T ........................................... 28  
40T5 40T 40TSTUDY AGENT AND INTERVENTIONS 40T ............................................................... 28  
40T5.1 40T 40TDrug Acquisition 40T .......................................................................................................... 28  
40T5.1.1 40T 40TPlerixafor: Provided by Manufacturer 40T ................................................................................. 28 
40T5.1.2 40T 40TG-CSF: Obtained Commercially 40T .......................................................................................... 29 
40T5.2 40T 40TDisposition and Dispensation 40T ....................................................................................... 29  
40T5.2.1 40T 40TFormulation, Packaging, and Labeling 40T ................................................................................ 29 
40T5.2.1.1 40T 40TPlerixafor Packaging from Manufacturer 40T .................................................................... 29 
40T5.2.1.2 40T 40TPlerixafor Repackaging for Study and/or Shipment to Study Participants 40T ................. 29 
40T5.2.1.3 40T 40TG-CSF Packaging from Manufacturer 40T ........................................................................ 29 
40T5.2.1.4 40T 40TG-CSF Repackaging for Study and/or Shipment to Study Participants 40T ...................... 29 
40T5.2.2 40T 40TLabeling of Study Drug 40T ....................................................................................................... 29 
40T5.3 40T 40TStudy Agent Storage and Stability 40T ............................................................................... 29  
40T5.3.1 40T 40TStorage at NIH-CC 40T ............................................................................................................... 30 
40T5.3.2 40T 40TShipment to Participants' Home 40T ........................................................................................... 30 
40T5.4 40T 40TStudy Agent Preparation and Administration 40T .............................................................. 30  
40T5.4.1 40T 40TSubject Preparation and Self-Injection 40T ................................................................................ 30 
40T5.4.2 40T 40TSubject Memory Aid: Injection Site, Injection Volume, Adverse Reactions 40T ...................... 30 
40T5.5 40T 40TDose -Adjustment and Therapeutic Schedule 40T ............................................................... 30  
40T5.6 40T 40TStudy Product Accountability Procedures 40T ................................................................... 30  
40T5.6.1 40T 40TPlerixafor 40T.............................................................................................................................. 30 
40T5.6.2 40T 40TG-CSF 40T .................................................................................................................................. 30 
40T6 40T 40TSTUDY SCHEDULE AND A CTIVITIES 40T .................................................................. 30  
40T6.1 40T 40TRecruitment 40T .................................................................................................................. 30  
40T6.2 40T 40TScreening 40T ...................................................................................................................... 31  
40T6.2.1 40T 40TLabs and Procedures 40T ............................................................................................................ 31 
40T6.2.2 40T 40TAssessment of Overall Health 40T .............................................................................................. 31 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 6 of 74 
 
 40T6.3 40T 40TInitial Evaluation and Baseline Assessment Period 40T ..................................................... 31  
40T6.3.1 40T 40TMeasurement of Immunological Markers 40T ............................................................................ 31 
40T6.3.2 40T 40TEvaluations: Dermatology, GYN, Dentistry, ENT, Audiology, and Clinical Photography 40T . 31 
40T6.3.3 40T 40TAdditional Evaluations if Clinically Indicated (e.g. PFT and CT of Chest and Sinus) 40T ........ 31 
40T6.3.4 40T 40TBaseline Measure of Bone Density and Spleen Size 40T ........................................................... 32 
40T6.3.5 40T 40TResearch Blood 40T .................................................................................................................... 32 
40T6.3.6 40T 40TWart and/or Skin Biopsy (optional) 40T ..................................................................................... 32 
40T6.3.7 40T 40TBone Marrow Biopsy (optional) 40T .......................................................................................... 32 
40T6.3.8 40T 40TQuality of Life Assessment of Period Prior to the Study 40T ..................................................... 32 
40T6.3.9 40T 40TIVIg and Prophylactic Antibiotics 40T ....................................................................................... 32 
40T6.3.10 40T 40TDetermining a Minimum Effective Dose for G-CSF 40T ....................................................... 32 
40T6.3.11 40T 40TPreparing for Study Drug Shipments and Study Drug Administration at Home 40T ............. 33 
40T6.3.12 40T 40TTraining and Practice for Submissions of Completed Subject Memory Aid 40T ................... 33 
40T6.3.13 40T 40TSelect a Local Medical Facility for Blood Draws at a Subject’s Home Locale 40T .............. 33 
40T6.4 40T 40TRandomization and Initiation of the First Study Dose 40T ................................................. 33  
40T6.4.1 40T 40TWashout Period Prior to the P 
PFirst Study/Comparator Dose (at least 2 days prior to 1 Pst
P dose) 40T
 33 
40T6.4.2 40T 40TAssessment of Overall Health (within 2 days prior to the 1 Pst
P dose) 40T ..................................... 33 
40T6.4.3 40T 40TConfirm Study Drug Shipment/Injection, Memory Aid, Local Labs, and Reporting 
Infections 40T ........................................................................................................................................... 33 
40T6.4.4 40T 40TLab Draw Prior to Injection of the 1 Pst
P Study/Comparator Dose 40T .......................................... 33 
40T6.4.5 40T 40TDay of the First Study/Comparator Dose (Day 0) 40T ............................................................... 34 
40T6.4.5.1 40T 40TPrior to Injection 40T.......................................................................................................... 34 
40T6.4.5.2 40T 40TAfter Study Drug Injection 40T .......................................................................................... 34 
40T6.4.5.3 40T 40TProcedures Prior to Leaving NIH-CC 40T ......................................................................... 34 
40T6.5 40T 40TEquilibration Period for the Treatment (8 weeks) 40T ........................................................ 34  
40T6.5.1 40T 40TBlood Draws at Subject’s Local Medical Facility Every 2 Weeks 40T ...................................... 34 
40T6.5.2 40T 40TDose May be Adjusted to Maintain ANC Between 500 -1500 cells/μL 40T ............................... 34 
40T6.6 40T 40TTreatment Period (52 weeks) 40T ....................................................................................... 34  
40T6.6.1 40T 40TAssessments at NIH-CC Every 4 Months 40T ............................................................................ 35 
40T6.6.1.1 40T 40TLabs 40T ............................................................................................................................. 35 
40T6.6.1.2 40T 40TAssessment of Overall Health and Safety 40T ................................................................... 35 
40T6.6.1.3 40T 40TMeasurement of Immunological Markers 40T ................................................................... 35 
40T6.6.1.4 40T 40TEvaluations and Consults for Assessment of Infections 40T .............................................. 35 
40T6.6.1.5 40T 40TResearch Blood 40T ........................................................................................................... 35 
40T6.6.1.6 40T 40TQuality of Life Assessment 40T ......................................................................................... 35 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 7 of 74 
 
 40T6.6.1.7 40T 40TSkin and Wart Biopsies (optional) 40T .............................................................................. 35 
40T6.6.2 40T 40TCBC w/diff, ESR, and Chemistries Every 2 Months at Subject’s Local Medic al Facility 40T .. 35 
40T6.6.3 40T 40TVisits to a Subject’s Local Provider for New or Worsening Infections 40T ............................... 35 
40T6.6.4 40T 40TEnd of Treatment (EOT) Visit for a Study Drug 40T ................................................................. 36 
40T6.7 40T 40TReverting to a Subject’s Pre -study Treatment 40T ............................................................. 36  
40T6.7.1 40T 40TWashout Period (2 Days) 40T ..................................................................................................... 36 
40T6.7.2 40T 40TMonitoring the G -CSF Dose (1 -2 Months) 40T .......................................................................... 36 
40T6.7.3 40T 40TStudy Completion Visit 40T ........................................................................................................ 36 
40T6.8 40T 40TEarly Completion of Treatment Due to Unwillingness or Inability to Receive Study 
Agent 40T ............................................................................................................................. 36  
40T7 40T 40TSTUDY PROCEDURES AND EVALUATIONS 40T ....................................................... 36  
40T7.1 40T 40TAbsolute Neutrophil Count (ANC) 40T .............................................................................. 36  
40T7.1.1 40T 40TTime of Day Measurement for ANC: Prior to Study Dose 40T .................................................. 37 
40T7.1.2 40T 40TTarget ANC during 8 week Equilibration Period (500 – 1500 cells/µL) 40T ............................. 37 
40T7.1.2.1 40T 40TSubjects with a Baseline ANC > 500 cells/µL 40T ............................................................ 37 
40T7.1.2.2 40T 40TSubjects Unable to Attain ANC >500 cells/μL During Equilibration, Despite Maximal 
Dose 40T 37 
40T7.1.3 40T 40TTarget ANC during the 52 week Treatment Period (500 – 7500 cells/µL) 40T.......................... 37 
40T7.1.4 40T 40TDose Range for Low-Dose Treatment 40T ................................................................................. 37 
40T7.2 40T 40TAdjusting the Study Dose to Meet ANC Goals 40T ........................................................... 38  
40T7.2.1 40T 40TInitial Study/Comparator Drug Doses during Equilibration Period 40T ..................................... 38 
40T7.2.2 40T 40TAdjustment for ANC <500 cells/µL 40T .................................................................................... 38 
40T7.2.3 40T 40TAdjustment for ANC between 500 – 1500 cells/µL in the Equilibration Period 40T ................. 38 
40T7.2.4 40T 40TAdjustment for ANC > 1500 cells/µL in the Equilibration Period 40T ...................................... 38 
40T7.2.5 40T 40TAdjustment for ANC > 7500 cells/µL in the Treatment Period 40T ........................................... 38 
40T7.3 40T 40TImmune Status: Leukocyte Immunophenotypes 40T .......................................................... 38  
40T7.4 40T 40TMedication Compliance: Study Drug and Prophylactic Antibiotics 40T ............................ 38  
40T7.4.1 40T 40TSubject Memory Aid 40T ............................................................................................................ 38 
40T7.4.1.1 40T 40TIVIg Treatment and Dose 40T ............................................................................................ 39 
40T7.4.1.2 40T 40TRecord Temperature for Fevers 40T ................................................................................... 39 
40T7.4.1.3 40T 40TCompliance with Prescribed Prophylactic Antibiotics 40T ................................................ 39 
40T7.5 40T 40TStudy Drug Side Effects and Toxicity 40T ......................................................................... 39  
40T7.5.1 40T 40TSubject Memory Aid 40T ............................................................................................................ 39 
40T7.5.1.1 40T 40TInjection Site Reaction 40T ................................................................................................ 39 
40T7.5.1.2 40T 40TBone (Skeletal) Pain: back, arms and legs 40T .................................................................. 39 
40T7.5.1.3 40T 40TOther Pain: shoulder, abdominal etc. 40T .......................................................................... 39 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 8 of 74 
 
 40T7.5.1.4 40T 40THeadache 40T ..................................................................................................................... 39 
40T7.5.1.5 40T 40TDizziness 40T ..................................................................................................................... 40 
40T7.5.1.6 40T 40TNausea 40T ......................................................................................................................... 40 
40T7.5.1.7 40T 40TVomiting 40T ..................................................................................................................... 40 
40T7.5.1.8 40T 40TDiarrhea 40T ....................................................................................................................... 40 
40T7.5.1.9 40T 40TSubject Specifies Other Symptoms or Adverse Events. 40T .............................................. 40 
40T7.5.2 40T 40TCBC, Chemistries, ESR, and Pregnancy for Women of Childbearing Potential 40T ................. 40 
40T7.5.3 40T 40TSplenic Enlargement 40T ............................................................................................................ 41 
40T7.5.3.1 40T 40TSpleen Ultrasonography 40T .............................................................................................. 41 
40T7.5.3.2 40T 40TSpleen Assessment as part of Physical Examination at Research Assessment 40T ........... 41 
40T7.5.4 40T 40TElectrocardiogram 40T ................................................................................................................ 41 
40T7.5.5 40T 40TEchocardiogram 40T ................................................................................................................... 41 
40T7.5.6 40T 40TDual -energy X-ray Absorptiometry (DEXA) Scans 40T ............................................................ 41 
40T7.6 40T 40TRate and Severity of Infections 40T .................................................................................... 41  
40T7.6.1 40T 40TSubject Memory Aid: Symptoms of Infections 40T ................................................................... 41 
40T7.6.1.1 40T 40TIncidence and Severity of Fever 40T .................................................................................. 41 
40T7.6.1.2 40T 40TNumber of Days with Fever 40T ........................................................................................ 41 
40T7.6.1.3 40T 40TChange in Severity of Chronic Infection 40T ..................................................................... 41 
40T7.6.1.4 40T 40TVisits to Local Provider for Medical Exam or Treatment 40T ........................................... 41 
40T7.6.1.5 40T 40TIncidence and Duration of Antibiotic  for Treatment 40T ................................................... 41 
40T7.6.2 40T 40TClinical Diagnosis and Treatment of Infections 40T................................................................... 42 
40T7.6.2.1 40T 40TLocal Provider Completes a Diagnosis and Treatment Form (option 1) 40T ..................... 42 
40T7.6.2.2 40T 40TSubject or Provider forwards Documents Relating to the Infection (option 2) 40T ........... 42 
40T7.6.3 40T 40TENT and Audiology Evaluation at NIH -CC 40T ........................................................................ 42 
40T7.6.4 40T 40TDental and Oral Evaluation 40T .................................................................................................. 42 
40T7.6.5 40T 40TPFT for Subjects with Chronic Respiratory Infections 40T ........................................................ 42 
40T7.7 40T 40TMonitoring Warts 40T ......................................................................................................... 42  
40T7.7.1 40T 40TPhotos of Infections and Warts 40T ............................................................................................ 42 
40T7.7.2 40T 40TRecording the Quantity and Severity of Warts 40T .................................................................... 42 
40T7.7.3 40T 40TDermatology Evaluation 40T ...................................................................................................... 43 
40T7.7.4 40T 40TGU/GYN Evaluation 40T ............................................................................................................ 43 
40T7.8 40T 40TSpecimen Preparation, Handling, and Shipping 40T .......................................................... 43  
40T7.9 40T 40TQuality of Life (SF36 v2) 40T ............................................................................................. 43  
40T7.10 40T 40TRequest for Excess Tissue 40T ............................................................................................ 43  
40T8 40T 40TPOTENTIAL RISKS AND BENEFITS 40T ...................................................................... 43  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 9 of 74 
 
 40T8.1 40T 40TPotential Risks of plerixafor 40T ......................................................................................... 43  
40T8.2 40T 40TPotential Risks for G -CSF 40T ............................................................................................ 45  
40T8.3 40T 40TRisks and Discomforts of Phlebotomy 40T ......................................................................... 46  
40T8.4 40T 40TRisks and Discomforts of Skin or Wart Biopsies 40T ......................................................... 46  
40T8.5 40T 40TRisks and Discomforts of Bone Marrow Biopsy 40T ......................................................... 46  
40T8.6 40T 40TRisks of Stopping G- CSF 40T ............................................................................................. 46  
40T8.7 40T 40TPotential Benefit 40T ........................................................................................................... 46  
40T8.7.1 40T 40TReduced Infections 40T ............................................................................................................... 47 
40T8.7.2 40T 40TImproved Drug Tolerability 40T ................................................................................................. 47 
40T8.7.3 40T 40TControl of Warts 40T .................................................................................................................. 47 
40T8.7.4 40T 40TIncreased Leukocyte Response 40T ............................................................................................ 47 
40T9 40T 40TRESEARCH USE OF STORED HUMAN SAMPLES, SP ECIMENS OR DATA 40T .... 47  
40T9.1 40T 40TIntended Use 40T ................................................................................................................. 47  
40T9.2 40T 40TStorage and Tracking 40T ................................................................................................... 47  
40T9.3 40T 40TSharing of Samples and Data 40T ....................................................................................... 48  
40T9.4 40T 40TReporting Loss or Unanticipated Destruction of Samples 40T ........................................... 48  
40T9.5 40T 40TDisposition of Samples 40T ................................................................................................ 48  
40T9.5.1 40T 40TRequest by Study Participant 40T ............................................................................................... 48 
40T9.5.2 40T 40TAt Completion of Study 40T ....................................................................................................... 48 
40T10 40T 40TREMUNERATION PLAN FOR SUBJECTS 40T ............................................................. 48  
40T11 40T 40TASSESSMENT OF SAFETY 40T ...................................................................................... 48  
40T11.1 40T 40TDocumenting, Recording, and Reporting Adverse Events 40T .......................................... 48  
40T11.2 40T 40TDefinitions 40T .................................................................................................................... 48  
40T11.3 40T 40TInvestigator Assessment of Adverse Events 40T ................................................................ 50  
40T11.3.1 40T 40TSeverity 40T ............................................................................................................................ 50 
40T11.3.2 40T 40TCausality 40T .......................................................................................................................... 50 
40T11.4 40T 40TInvestigator Reporting Responsibilities to the Sponsor 40T ............................................... 51  
40T11.4.1 40T 40TAdverse Events 40T ................................................................................................................ 51 
40T11.4.2 40T 40TSerious Adverse Events 40T ................................................................................................... 51 
40T11.4.3 40T 40TUnanticipated Problems 40T ................................................................................................... 52 
40T11.4.4 40T 40TProtocol -Specified Events 40T ............................................................................................... 52 
40T11.4.5 40T 40TPregnancy 40T ........................................................................................................................ 52 
40T11.5 40T 40TInvestigator Reporting Responsibilities to the NIAID IRB 40T ......................................... 52  
40T11.5.1 40T 40TExpedited Reporting 40T ........................................................................................................ 52 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 10 of 74 
 
 40T11.5.2 40T 40TWaiver of Reporting Anticipated Protocol Deviations, Expected UPnonAEs and Deaths 40T
 52 
40T11.5.3 40T 40TAnnual Reports 40T ................................................................................................................ 52 
40T11.6 40T 40TFollow-up of Adverse Events and Serious Adverse Events 40T ......................................... 53  
40T11.7 40T 40TInvestigator Initiated Trial (IIT) Sponsor Obligations and Reporting Responsibilities 40T 53 
40T11.8 40T 40THalting Criteria for the Protocol 40T .................................................................................. 54  
40T11.8.1 40T 40TReporting of Study Halting 40T .............................................................................................. 54 
40T11.8.2 40T 40TResumption of a Halted Study 40T ......................................................................................... 54 
40T11.9 40T 40TPausing Criteria for a Subject 40T ...................................................................................... 54  
40T11.9.1 40T 40TReporting of Pausing for a Subject 40T .................................................................................. 54 
40T11.9.2 40T 40TResumption of a Paused Study 40T ........................................................................................ 54 
40T11.10 40T 40TWithdrawal Criteria for an Individual Subject 40T ............................................................. 55  
40T11.11 40T 40TAdditional Enrollment for Withdrawn Subjects 40T .......................................................... 55  
40T12 40T 40TSAFETY OVERSIGHT AND MONITORING PLAN 40T ............................................... 55  
40T12.1 40T 40TSafety Review and Communication Plan 40T ..................................................................... 55  
40T12.2 40T 40TSponsor Medical Monitor 40T ............................................................................................ 55  
40T12.3 40T 40TData and Safety Monitoring Board 40T .............................................................................. 55  
40T12.4 40T 40TProcedures for Emergency Unblinding 40T ........................................................................ 55  
40T13 40T 40TCLINICAL MONITORING STRUCTURE 40T ................................................................ 56  
40T13.1 40T 40TSite Monitoring Plan 40T .................................................................................................... 56  
40T14 40T 40TSTATISTICAL CONSIDER ATIONS 40T ......................................................................... 56  
40T14.1 40T 40TStudy Hypotheses 40T ......................................................................................................... 56  
40T14.2 40T 40TSample Size Justification 40T ............................................................................................. 56  
40T14.3 40T 40TStudy Population 40T .......................................................................................................... 57  
40T14.4 40T 40TDescription of Analysis 40T ................................................................................................ 57  
40T14.4.1 40T 40TEfficacy Analysis – Infection Severity Score (ISS) 40T ......................................................... 57 
40T14.4.1.1 40T 40TInfection -related Events 40T .............................................................................................. 57 
40T14.4.1.2 40T 40TSeverity of Fever for an Infection -related Event 40T ......................................................... 58 
40T14.4.1.3 40T 40TLevel of Antibiotic Treatment for an Infection-related Event 40T ..................................... 58 
40T14.4.1.4 40T 40TExtent of Hospitalization for an Infection-related Event 40T ............................................ 58 
40T14.4.2 40T 40TMethod of Analysis 40T ......................................................................................................... 58 
40T14.4.3 40T 40TInterim Analysis 40T .............................................................................................................. 59 
40T14.4.4 40T 40TFutility Monitoring 40T .......................................................................................................... 59 
40T14.4.5 40T 40TSafety Analysis 40T ................................................................................................................ 59 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 11 of 74 
 
 40T14.4.6 40T 40TSecondary Analysis 40T ......................................................................................................... 59 
40T14.4.6.1 40T 40TSecondary endpoints 40T ................................................................................................... 59 
40T14.4.6.2 40T 40TIncidence and Duration of Infection-related Event 40T ..................................................... 59 
40T14.4.6.3 40T 40TIncidence and Duration of Fever 40T ................................................................................. 59 
40T14.4.6.4 40T 40TIncidence and Duration of Antibiotic Treatment 40T ........................................................ 60 
40T14.4.6.5 40T 40TIncidence and Duration of Hospitalization 40T .................................................................. 60 
40T14.4.6.6 40T 40TSeverity of Chronic Infections 40T .................................................................................... 60 
40T14.4.6.7 40T 40TUse of Prophylactic Antibiotics 40T .................................................................................. 60 
40T14.4.6.8 40T 40TControl of Warts 40T .......................................................................................................... 60 
40T14.4.6.9 40T 40TChange of Leukocyte Blood Counts 40T ........................................................................... 60 
40T14.4.6.10 40T 40TQuality of Life and Subject Preference Assessment 40T ............................................... 61 
40T14.4.7 40T 40TRandomization 40T ................................................................................................................. 61 
40T15 40T 40TETHICS/PROTECTION OF  HUMAN SUBJECTS 40T ................................................... 61  
40T15.1 40T 40TInformed Consent Process 40T ............................................................................................ 61  
40T15.2 40T 40TSubject Confidentiality 40T ................................................................................................. 62  
40T16 40T 40TDATA HANDLING AND RECORD KEEPING 40T ........................................................ 62  
40T16.1 40T 40TData Management Responsibilities 40T .............................................................................. 62  
40T16.2 40T 40TData Capture Methods 40T .................................................................................................. 62  
40T16.3 40T 40TTypes of Data 40T ............................................................................................................... 62  
40T16.4 40T 40TSource Documents and Access to Source Data/Documents 40T ........................................ 62  
40T16.5 40T 40TStudy Records Retention 40T .............................................................................................. 63  
40T17 40T 40TREFERENCES 40T ............................................................................................................. 64  
40TAPPENDIX A: SCHEDULE  OF PROCEDURES AND E VALUATION 40T ................................. 67  
40TAPPENDIX B: FDA APPROVED PACKAGED INSERT: PLERIXAFOR 40T ............................. 69  
40TAPPENDIX C: FDA APPROVED PACKAGE INSERT:  G-CSF 40T ............................................. 70  
40TAPPENDIX D: INFECTION SEVERITY SCORE (IS S) 40T ........................................................... 71  
40TAPPENDIX E: DOSING OF PLEXIFOR IN RENAL IMPAIRMENT 40T ..................................... 72  
40TAPPENDIX F: SAMPLE SUBJECT MEMORY AID 40T ............................................................... 73  
40TAPPENDIX G: EVALUATION OF INFECTION FORM 40T ......................................................... 74  
 
  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 12 of 74 
 
 LIST OF TABLES  
 
40TTable 1:  Sample size required to achieve 90% power under different assumptions for the mean response 
on G -CSF and plerixafor.  Power formula based on a two-sided two sample  t -test with alpha=0.05 using 
the period 1 minus period 2 change in TISS scores as the primary outcome. A standard deviation of 10 for the difference is assumed.
40T .......................................................................................................................... 56 
 
LIST OF FIGURES  
 
40TFigure 1 :  Plerixafor May Reduce Infection Incidence in Patients with WHIM Syndrome. 40T ..................... 25 
 
  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 13 of 74 
 
 LIST OF ABBREVIATIONS  
 
ADL  Activities of Daily Living  
ADR  Adverse Drug Reaction  
AE Adverse Event/Adverse Experience  
AML  Acute Myeloid Leukemia  
ANC  Absolute Neutrophil Count  
AR Adverse Reaction  
ARDS  Acute Respiratory Distress Syndrome  
 b.i.d.   Twice per day (bis in die)  
CFR  Code of Federal Reg ulations  
CBC  Complete Blood C ount (with differential ) 
CC Clinical Center  
CrCl  Creatinine C learance (calc ulated)  
CRF  Case Report F orm 
CRIS  Clinical Research Information System (for NIH Clinical Center)  
CSO  Clinical  Safety Office  
CXCL12  CXC chemokine ligand 12, aka SDF -1 
CXCR4  CXC chemokine receptor 4  
 DEXA   Dual -energy X -ray Absorptiometry  
DCR  Division of Clinical Research  
 DSMB   Data and Safety Monitoring Board  
 EBV   Epstein -Barr Virus  
ECHO  Echocardiogram  
 EOT  End of Treatment  
EKG  Electrocardiogram  
ESR Erythrocyte Sedimentation Rate  
FDA  Food and Drug Administration  
GCP  Good Clinical Practices  
 G-CSF  Granulocyte Colony -Stimulating F actor  
 GM-CSF  Granulocyte M acrophage Colony -Stimulating F actor  
 GRK   G Protein -Coupled Receptor Kinase  
GU Genitourinary  
GYN  Gynecology  
HIV Human Immunodeficiency V irus 
HPV  Human Papillomav irus 
HSC  Hematopoietic Stem C ell 
ICH International Conference on Harmonization  
IgA, IgE, IgG, IgM  Immunoglobulins A, E, G, M  
 IIT  Investigator Initiated Trial  
IND Investigational New Drug  
IRB Institutional Review Board  
ISS Infection Severity Score  
 IVIg   Intravenous I mmunoglobulin  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 14 of 74 
 
 LHD  Laboratory of Host Defenses  
LMI Laboratory of Molecular Immunology  
LMF  Local Medical Facility  
MDS  Myelodysplastic Syndrome  
MED  Minim um Effective D ose 
MM Multiple M yeloma  
NCI National Cancer Institute  
NHL  non-Hodgkin ’s lymphoma  
 NIAID   National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
NIH-HRPP  National Institutes of Health – Human Research Protection Program  
 NIH-CC  National Institutes of Health Clinical Center  
OCRPRO  Office of Clinical Research Policy and Regulatory Operations  
OHRP  Office for Human Research Protection  
PFT Pulmonary Function Test  
PI Principal Investigator  
PT Prothrombin Time  
PTT Partial Thromboplastin Time  
 QOL   Quality of Life  
RCHSPP  Regulatory Compliance and Human Subjects Protection Program  
SAE  Serious Adverse Event  
SAR  Suspected Adverse Reaction  
SCN  Severe  Congenital Neutropenia  
SRCP  Safety Review and Communication Plan  
 SDF-1  Stromal Cell -Derived factor -1, aka CXCL12  
SQ Subcutaneous  (Injection)  
SUSAR  Serious and Unexpected Suspected Adverse Reaction  
TISS  Total Infection Severity Score  
TPN  Total Parenteral Nutrition  
WBC  White Blood Cell Count  
WHIMS  Warts, Hypogammaglobulinemia, Infections, and Myelokathexis 
Syndrome  
UP Unanticipated Problem  
UPnonAE  Unanticipated Problem that is not an Adverse Event  
  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 15 of 74 
 
 PROTOCOL SUMMARY  
 Full Title:  A Phase III , Double -blind , Randomized, Crossover Study of P lerixafor  Versus 
G-CSF in t he Treatment of Patients with WHIM Syndrome  
 
Short Title: Plerixafor vs. G-CSF in WHIMS 
 
Clinical Phase:  III 
 
IND Sponsor:  OCRPRO/DCR/ NIAID  
 
Conducted by:  Laboratory of Molec ular Immunology/NIAID  
 
Principal Investigator:   David H. McDermott , MD  
 Sample Size:   N=20  
 
Accrual Ceiling:   n = 30 
 
Study Population:   Subjects (≥10 and ≤75 years of age) with WHIMS   
 
Accrual Period:  36 months  
 
Study Design:  This is a double -blind ed, randomized, crossover study  
comparing the  efficacy of  the chemokine receptor CXCR4 antagonist  
plerixafor  to G-CSF in subjects with a clinical dia gnosis of WHIMS and 
mutations in the C -terminus of chemokine receptor CXCR4. Eligible s ubjects 
who give informed consent  are randomized to 1 year of treatment with either  
plerixafor  or G-CSF , followed by a crossover to the second  drug for 1 year . 
Each treatment arm is preceded by  a 2-day washout  period  followed by an 8-
week  equilibration period during which study drug dosing is initiated and 
adjusted  to establish an ANC of approximately 500- 1500 cells/μL . A subject’s 
ANC is moni tored every 2 months during the  one-year treatment period s and 
study drug dosage  adjusted for ANC ≤500 cells/µL  or ≥ 7500 cells/µL . 
Participants maintain a study Memory Aid  in which they record daily 
treatments and  any new symptoms. After complet ing both treatment s, subjects 
are offered  G-CSF and enter a post -treatment observation period during which 
they continue to submit the study Memory Aid . The  study c ompletion visit 
occurs 5-6 months after  the last day of  the second year of treatment .  
 Study Duration:   6 years  
    
Study Agent/Intervention : plerixafor  (Mozobil™ ) 
Comparator:   G-CSF (Neupogen
PTM
P, filg rastim) 
 
Primary Objective:  Compare the severity of infection during treatment with each drug  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 16 of 74 
 
      
Secondary Objectives:    
1) Compare component measures of infections.  
2) Measure the control of warts with plerixafor  versus G-CSF. 
3) Demonstrate the safety of plerixafor  and G -CSF as long -term therapy.  
4) Compare the symptoms of chronic infections.  
5) Compare quality of life (QOL).  
6) Compare drug tolerability  and assess subject  drug preference . 
7) Compare the increase of leukocyte levels from baseline.  
 
Exploratory Objective:    Measure type, location, and cause of i nfection s. 
 
Primary Endpoint: The primary endpoint is infection severity, which is measured as a composite 
of multiple weighted parameters according to rules defined in 40TAppendix D 40T. 
 
Secondary Endpoints:    
1) Component  measures of i nfection s: incidence and duration of infections, 
fever, antibiotic treatment, and  hospitalization . 
2) Control of warts as defined by at least a 50% reduction in numbers, areas 
or size of existing warts, or in  new warts occurring during treatment . 
3) Blood count and immunological parameters.  
4) Clinical measures of c hronic infection . 
5) Treatment  side effects. 
6) Quality of life scores. 
7) Treatment preference. 
  
Exploratory Endpoint :  Identify causative organisms and locations of infections in WHIM S patients.   
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 17 of 74 
 
 PRÉCIS  
 Warts, hypogammaglobul inemia, infections, and myelokathexis syndrome  (WHIMS) is a rare combined 
primary immunodeficiency disorder caused by  gain-of-function mutations in the gene for the chemokine 
receptor CXCR4 .  Normally, CXCR4 is expressed on most leukocyte  subsets and functions in part to 
promote hematopoietic stem cell (HSC) and neutrophil homing to and retention in bone marrow .
P  
PWHIM 
mutations alter the CXCR4 carboxyl terminus , which  enhances and prolongs receptor signaling. ( 40T1 40T) As a 
result, egress of normally produced and functional neutrophils from the bone marrow to the blood is 
impaired causing neutropenia, a bone marrow pathologic finding referred to as my elokathexis. A similar 
mechanism may also affect other leukocyte subsets since WHIM patients usually are panleukopenic.  
Consequently, WHIM patients are predisposed to frequent acute bacterial infections, especially in the sinopulmonary tract, that may cause chronic morbidity, respiratory insufficiency and in some cases premature death.  WHIM patients also have marked difficulty clearing infections with Human 
Papillomavirus ( HPV), resulting in persistent cutaneous and anogenital warts that in several report ed 
cases have evolved into cancer. Several deaths have also occurred due to cancer associated with Epstein - 
Barr virus (EBV) infection.  Therapies currently  used for WHIMS are non-specific and expensive, and 
include  Granulocyte Colony -Stimulating Factor  (G-CSF) (the drug currently approved by the Food and 
Drug Administration (FDA) to treat severe congenital neutropenia), intravenous immunoglobulin (IVI g), 
and prophylactic antibiotics .  None of these measures has been formally evaluated for efficacy in WHIM 
syndrome  (WHIMS); however, in our clinical experience b ased on the treatment of 24 WHIM patients  
seen at the National Institutes of Health (NIH) since 2006, recurrent bacterial infections continue to occur , 
despite the fact that the absolute neutrophil count (ANC ) can be readily maintained above 500 
cells/microliter by G-CSF and IgG levels can be restored to the normal range by IVIg . Thus, there 
continues to be a major unmet medical need for effective therapy in WHIMS  despite the availability and 
application of best therapy for neutropenia and hypogammaglobulinemia in these patients.  Plerixafor 
(Mozobil™) i s a specific small molecule antagonist of CXCR4, licensed by the FDA for HSC 
mobilization for transplantation in cancer, and is th erefore a logical candidate for molecularly targeted 
treatment of WHIMS .(
40T2 40T)  The goal of treatment would be to reduce CXCR4 signaling to normal, not to 
zero, thus, absent any off-target effects, targeted chronic treatment with this agent may be safe.  In this 
regard, 2 recent short term Phase I dose- escalation studies of plerixafor, one from our group,  in a total of 
9 patients  demonstrated that the drug could safely  mobilize not only neutrophils, but also all other 
leukocy te subsets that are decreased in the blood of WHIM  patients. ( 40T3, 4 40T)  A follow -up Phase I study , 
conducted by our group, in 3 patients given plerixafor 0.02- 0.04 mg/kg/d for 6 months demonstrated that 
these hematopoietic effects were durable.(5)  Moreover, the frequency of infection was reduced on 
plerixafor as compared to retrospective data mined for the three years before starting therapy and 
prospective data collected for one year after ending therapy, even though 2 of the patients were taking G-
CSF during the comparison time periods.  No new warts occurred during treatment and several existing warts improved or resolved. Although these results are encouraging, the small number of patients studied, limited duration of drug treatment, and retrospective mining of control data leave open to question whether plerixafor is truly efficacious for clinical outcomes in WHIMS .  The  randomized, double -
blind ed, crossover trial described here is designed to answer this question by est ablishing the long-term 
safety and clinical efficacy (primar y endpoint: infection severity; multiple secondary endpoints including 
wart control) of plerixafor as compared to G-CSF in the treatment of WHIMS patients 10-75 years of age. 
G-CSF as a comparator  is required because of its approved use in patients with severe congenital 
neutropenia (SCN).  
 
Brief outline of study —we intend to randomize 20 patients and treat them in a double -blinded manner for 
1 year with G -CSF and 1 year with plerixafor  using a crossover design to allow direct comparison of 
infection severity  during treatment with both agents , at doses determined by the patient’s individual 
neutrophil response. A schedule of events has been provided in 
40TAppendix A 40T. Data will be analyzed as 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 18 of 74 
 
 specified in the Statistics section ( Section 14) after randomization .  Tolerability and patient drug 
preference will also be assessed.   
 
 
STUDY SCHEMA 
 
 
 
  2d 8w  52w  2d  8w  52w  
 Randomize 
to AB Arm   
Wash 
Out 
 Equilibration  Treatment A    
Wash 
Out Equilibration  Treatment B  
Screening & Initial 
Evaluation   
      
  Post Treatment 
Study Completion 
Visit ( approx. 20w)  
 Randomize 
to BA Arm   
Wash 
Out Equilibration  Treatment B    
Wash 
Out Equilibration  Treatment A  
 
 
w = week(s)  
d = day(s)  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 19 of 74 
 
 1 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  
1.1 Background Information 
1.1.1 CXCR4  
CXCR4 is a member of the chemokine receptor family, which consists of 18 related 7 transmembrane -
domain, G protein-coupled chemoattractant receptors that regulate leukocyte trafficking. (6, 40T7 40T) According 
to studies in gene knockout mice, CXCR4 is essential for life and  plays a fundamental role in the 
hematopoietic, cardiovasc ular, reproductive, and nervous systems during embryonic development .( 40T8 40T) In 
the hematopoietic system, CXCR4 is important for hematopoietic stem  cell and neutrophil trafficking 
between blood and bone marrow .  In particular, reduced CXCR4 signaling promotes egres s of these cells 
from marrow whereas increased  CXCR4 signaling promotes homing to and retention of these cells in 
bone marrow. ( 40T9 40T) CXCR4 is  also an important HIV co -receptor (with CD4) used by the virus for target 
cell infection, but only for a minority of HIV strains, which  are found in patients mainly during the  late 
stages of disease. ( 40T10 40T) 
1.1.2 WHIMS   
Warts, h ypogammaglobul inemia, infections, and myelokathexis s yndrome (WHIMS ) is a rare congenital 
immunodeficiency disorder caused by various mutations that increase CXCR4 signaling. ( 40T11, 12 40T). All 
cases that have been genetically characterized to date involve trun cation and missense mutations in the 
intracellular tail of the receptor  that are inherited in an autosomal dominant manner. ( 40T1, 13 40T) This domain 
normally mediates negative regulation of the receptor through G protein-coupled receptor kinase (GRK) -
mediated phosphorylation and beta -arrestin -mediated internalization, providing a potential mechanism for 
the increased signaling that is observed. ( 40T14 40T) Consistent with this, truncated WHIMS receptors have been 
reported to undergo reduced  ligand -dependent receptor down -regulation.( 40T15, 16 40T) One WHIMS patient  
has been identified who lacks CXCR4 mutations , however this individual has  decreased  expression o f 
GRK3, which normally mediates CXCR4 desensitization. ( 40T17 40T) Another family has recently been 
identified with 2 affected members with  a recessive mutation in CXCR2.  Thus, WHIMS can be thought 
of as a disease caused by excessive CXCR4 function  or insufficient CXCR2 function, which  validates the 
fundamental role of these receptors in homeostatic leukocyte trafficking in humans . A mouse model in 
which a human WHIMS CXCR4 mutation (S338X)  was knocked into one mouse CXCR 4 locus 
phenocopies panleukopenia and revealed abnormal immune organ architecture .( 40T18, 19 40T) It is possible that 
mutations  in other immunoregulatory gene s may also cause a similar syndrome .  
 The acronym WHIMS  highlights four  clinical manifest ation s of the disease: warts, 
hypogammaglobul inemia, infections, and myelokathexis. Warts are refractory to medical treatment in 
WHIMS  and can evolve into fatal skin and anogenital cancer . Hypogammaglobul inemia is moderate and 
variable.  Nevertheless,  WHIMS patients have been reported to have poor immunologic memory after 
vaccination, and the resul ting low levels of immunoglobul ins may predispose them to frequent 
sinopul monary infections .(
40T20 40T) Perhaps the earliest and most highly penetrant clinical finding is 
neutropenia , usually severe,  which appears to be caused by  abnormal retention of mature neutrophils , a 
critical effector cell in innate immunity, in the bone marrow.  Most patients also have panleukopenia. This 
picture, which is known as myelokathexis, the ‘M’ in WHIMS, further predispos es the patient  to typical 
bacterial skin, soft tissue, an d sinopul monary infections. When the absolute neutrophil count (ANC) is  
reduced  below ~500 cells/µL  in patients receiving cytoreductive therapy  for diseases such as cancer , the 
risk of infection  with bacteria and fungi  increases: however , the precise relationship between ANC and 
infection risk in WHIMS has not been defined . During infection in WHIMS patients , neutropenia often 
improves and may temporarily normalize, suggesting that the inhibition of marrow release of neutrophils can be ove rcome in the presence of infection. However, the end resul t of frequent infections in WHIMS 
patients can be serious, with  loss of hearing, teeth, and lung function.   Dental disease consists of HPV 
related oral cancers, severe caries, periodontitis, dental abscesses, and premature tooth loss.  Older 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 20 of 74 
 
 patients can develop severe bronchiectasis resembling cystic fibrosis, and fatal respiratory failure. Case 
reports of fatal meningitis and Epstein- Barr virus-induced lymphoma in patients with WHIMS  provide 
eviden ce that other immunological problems present in WHIMS patients are clinically significant.( 40T21, 
22 40T) In addition, an increased prevalence of tetralogy of Fallot has been observed in WHIM patients.( 40T23 40T) 
 Current therapeutic recommendations in WHIMS are non-specific, expensive, associated with significant 
side effects, and  based on limited direct clinical data. Daily or every other day injection of G -CSF is 
commonly given to increase the ANC , based on a  placebo -controlled clinical trial that demonstrated G-
CSF safety and efficacy  in reducing the risk of infection in patients with severe congenital neutropenia  
(SCN) of various etiologies .(
40T24 40T) On the basis of this trial, SCN was approved as an indication for G-CSF 
therapy.  However, only a few patients with WHIMS were included in the trial, so that the actual efficacy of G-CSF in modulating clinical endpoints  specifically  in WHIMS is not known. Monthly infusions of 
intravenous immunoglobul in (IVIg) or subcutaneous immunoglobulin are also given to those WHIMS 
patients who have severe hypogammaglobulinemia ; however , its efficacy in this setting has not been 
studied .(
40T1 40T) Anecdotal evidence suggests that together these measures may not affect HPV infection in 
WHIMS patients , nor would they be expected to,  and do not fully prevent infections  (Figure 1) .( 40T25 40T) 
Thus, there is a clear unmet medical need for new treatments in these patients.  For th ese reason s and 
because of expense and side effect considerations (see below) , it is clear that direct studies quantifying the 
clinical efficacy of G-CSF specifically  in WHIMS  as well as development of more specific treatment 
modalities in WHIMS are needed.  
1.2 Description of Study Agent : Mozobil™  (plerixafor ) 
The Food and Drug Administration (FDA) approve d plerixafor  (Mozobil™)  injection in 2008 for use in 
combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and 
subsequent autologous transplantation in patients w ith non -Hodgkin’s  lymphoma  (NHL)  and multiple 
myeloma  (MM).( 40T26 40T) Plerixafor  was initially developed as an antiretro viral compound for the treatment 
of human immunodeficiency virus (HIV). ( 40T27 40T) It was found to be a specific and reversible inhibitor of the 
chemokine receptor and HIV co -receptor CXCR4, and its plasma concentrations closely correlated with 
the ability to inhibit CXCR4 HIV viral entry into target cells.  While initial studies showed that it was a 
safe and effective antiviral drug in animals and humans, CX CR4-using virus is not common in initial HI V 
infection and the drug is not orally bioavailable, limiting its usef ulness for treating HIV. However in early 
human studies, it was noted to cause a dramatic and rapid increase in white blood cell count (WBC).  
 This was consistent with other studies in mice showing that CXCR4 is a strong bone marrow retention 
factor for leukocytes in general and neutrophils and CD34
P+ 
Phematopoietic stem cells specifically. This 
prompted successf ul trials of plerixafor  in animals and humans for the purpose of CD34 P+ 
Phematopoietic 
stem cell mobilization. This is a procedure in which apheresis of donor blood is done to separate and 
remove CD34 P+ 
Pcells, which allows for immune system reconstitution after high dose chemotherapy for 
cancer. Plerixafor  is effective either by itself or in combination with granul ocyte  colony -stim ulating factor 
(G-CSF), which is the agent that has traditionally been used for this purpose. In Phase III clinical studies 
that led to its licensure in the US, it was found that there was a dramatic, statisti cally significant increase 
in the percentage of diffic ult to mobilize (because of prior chemotherapy) individuals who reached the 
target number of cells collected when plerixafor  was used with G-CSF compared to when  G-CSF was 
used alone. ( 40T28, 29 40T) 
 Clinical Pharmacology / Mechanism of Action: Plerixafor  is a specific antagonist of the CXCR4 
chemokine receptor and blocks binding of its cognate ligand, stromal cell -derived factor -1 (SDF -1 also 
known as CXCL12). Both SDF-1 and CXCR4 are recognized to play a role in the trafficking and homing 
of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to the marrow matrix, either directly via SDF-1 or through the 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 21 of 74 
 
 induction of other adhesion molec ules. Treatment with plerixafor  resulted in leukocytosis and elevations 
in circ ulating HSC  in mice, dogs, and humans.  
 
Pharmacokinetics: Pharmacokinetic studies in normal volunteers and cancer patients have shown that 
plerixafor is rapidly absorbed after subcutaneous (SQ ) injection.( 40T10, 30 40T) Peak plasma concentration is 
observed at 30 -60 minutes after a single 0.24 mg dose and the half -life has been estimated at 
approximately 5 hours. The drug is eliminated  through the kidneys with 70% excreted unchanged in the 
urine in 24 hours. There are no reported drug-drug interactions, and studies to date have found no 
interactions with the cytochrome P450 system.  In vitro , the drug was negative in  tests of mutagenesis. 
However, in vivo, it has been found to be teratogenic in animals and coul d be excreted in breast milk .  It 
is therefore contraindicated in pregnant women or nursing mothers . The teratogenicity may be a direct 
effect of blocking CXCR4 since animal studies have found the receptor to be critical for several aspects of embryogenesis and immune system development.(8,31,32)  
Adverse Reactions: The data described herein reflect 2 randomized studies in patients with NHL and 
MM, in which 301 patients treated with plerixafor  in combination with G -CSF were compared to 292 
patients who were treated with placebo and G-CSF.(
40T28,29 40T) Side effects attributed to the drug were 
relatively minor and consisted of mild injection site reactions and gastroi ntestinal complaints . 
( 40TAppendix B 40T) In partic ular, the most common adverse reactions (> 10%) reported in patients who 
received plerixafor  in conjunction with G -CSF were diarrhea, nausea, fatigue, injection site reactions, 
headache, arthralgia, dizziness, and vomiting.  
 
UGastrointestinal complaints U: Nausea, vomiting, and diarrhea were frequently reported in cancer patients 
treated with both plerixafor  and G -CSF, but also may be attributable to the chemotherapy, the apheresis, 
or the underlying disorder  as these have not been a problem in WHIM S patients treated to date. 
 
UInjection site reactions U: In the randomized studies, 34% of patients with NHL or MM had mild to 
moderate injection site reactions at the site of subcutaneous administration of plerixafor .(28,29 ) These 
included erythema, hematoma, hemorrhage, induration, inflammation, irritation, pain, paresthesia, 
pruritus, rash, swelling, and urticaria.  In contrast, i n 2 studies of the drug in WHIM S patients, injection 
site reactions occurred but consisted only of small, self-resolving areas of erythema and pruritus  occurring 
mainly at doses of 0 .08 mg/kg and above. ( 40T3, 4 40T) In the patients treated for 6 months with low doses (0.01-
0.04 mg/kg) no injection site reactions were observed .(5) 
 
UOther adverse events: U Mild to moderate systemic reactions were observed in fewer than 1% of patients in 
cancer studies approximately 30 minutes after  plerixafor  administration. These events included one or 
more of the following: urticaria, periorbital swelling, dyspnea, hypoxi a, vasovagal reactions, orthostatic 
hypotension, and/or syncope . Symptoms generally responded to treatments (e.g., antihistamines, 
corticosteroids, hydration, or supplemental oxygen) or resolved spontaneously  (Appendix B ), and have 
not been observed in studies of WHIMS patients.  
1.2.1 Summary of Previous Pre -Clinical Studies  
In vitro studies have demonstrated that plerixafor  is specific for CXCR4 and is a reversible inhibitor of 
the natural ligand's (SDF -1, aka CXCL12 ) ability to bind the receptor.  Plerixafor  has a very similar ability 
to bind and block the signaling of  both wild type and WHIM variants of CXCR4.( 40T2 40T) Long-term 
administration to mice, rats, and monkeys was found to be safe; however, in high doses (10 times > the highest human dose) in pregnant rats, the drug was found to be teratogenic causing fetal mortality. Also in rats, increased spleen weight was observed after 2 to 4 weeks of daily administration at high doses – 
4 times the highest human dose  (Appendix B). 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 22 of 74 
 
 1.2.2 Summary of Relevant Clinical Studies 
Plerixafor  in combination with G -CSF has been used in more than 980 patients enrolled in 16 clinical 
studies for the purpose of stem cell mobilization as reported by the manufacturer, Genzyme/Sanofi  Corp, 
to the FDA. In one  randomized study of 298 patients with NHL  where all patients were given 0.24 mg/kg 
of the drug subcutaneously  daily for 1 to 7 days (median, 2 days), 59% of those who received the drug 
combination were able to achieve the collection goal of 5 million CD34+ cells/kg versus only 20% who received G-CSF alone (p<0.001).(
40T28 40T) In a second randomized study, 302 patients with m ultiple myeloma 
were mobilized in the same way and 72% achieved the collection goal of 6 million CD34+ cells/kg versus 
only 34% of those who received G -CSF alone (p<0.001).( 40T29 40T) In Phase I studies by McDermot t, et al and 
Dale, et al ., 9 adult WHIM S patients were treated with a dose escalation of plerixafor  up to the FDA 
approved dose of 0.24 mg/kg/d and were found to rapidly mobilize all leukocyte subsets to the blood that 
are decreased in the disease.( 40T3, 4 40T)  The lowest dose, 0.02 mg/kg/d , was able to increase the neutrophils to 
greater than 500 cells/µL  of blood which is considered the boundary below which an increased risk of 
bacterial and fungal  infection may occur .  One of the 9 had to stop the dose escalation at 0.08 mg/kg 
because of development of a n acute exacerbation  of chronic bronchitis and possible pneumonia  ( 40T4 40T), but 
both studies concluded that the drug was safe and effective and that this was proof of principle that 
antagonism of CXCR4 co uld reverse panleukopenia.  However, these studies left open the question as to 
whether long- term, low dose therapy wo uld be practical, safe, and clinically effective.  We have 
compl eted a 6 -month study of 3 ad ult WHIMS patients given 0.01 -0.02 mg/kg twice/day and found that 
the leukocyte mobilization effects were durable and that the drug was safe for administration  up to 6 
months .(5).  
 Moreover, the frequency of infection was reduced on plerixafor as compared to retrospective data mined for the three years before starting therapy and prospective data collected for one year after ending therapy.  
No new warts occurred during treatment and multiple existing warts improved or resolved. Although 
these results are encouraging, the small number of patients studied, limited duration of drug treatment, 
and retrospective mining of control data leave open to question whether plerixafor is truly efficacious for clinical outcomes in WHIMS .  The goal of the current study is to answer this question choosing as the 
primary endpoint the severity of infections compared between  the plerixafor  treatment arm and the 
comparator G-CSF treatment arm using a double -blind ed, crossover design .  G-CSF is required as a 
comparator because of its approved use in patients with SCN. 
1.3 Description of Comparator Treatment: G -CSF  
G-CSF is FDA -licensed and the standard of care for severe chronic neutropenia, and will be used as the 
control or comparator drug in this study. (
40T24 40T) (see 40TAppendix C 40T) G-CSF is a recombinant human protein 
produced in E. coli that is identical in amino acid sequence with the exception o f an additional N-terminal 
methionine to a naturally occurring cytokine  made by human monocy tes, fibroblasts, and endothelial 
cells.  G-CSF acts on specific receptors to regulate the proliferation and differentiation of neutrophil 
progenitor s, and augment s the bone marrow release and  function of mature neutrophils.  It has minimal 
effects on other hematopoietic cell types.  Its effect on bone marrow release of neutrophils is mediated in part by interfering with CXCL12 availability at CXCR4. 
1.3.1 Summary of Relevant Clinical Studies  
In Phase I studies involving 96 subjects with no myeloid malignancies‚ G- CSF administered at doses of 1 
to 70 µg/kg/day resulted in a dose -dependent increase in circulating neutrophil counts. (33-35 ) Neutrophil 
counts returned to baseline within 4 days after disco ntinuation of G -CSF therapy. The absolute monocyte 
count was reported to increase in a dose- dependent manner in most subjects receiving G -CSF; however‚ 
the percentage of monocytes in the differential count remained within the normal range. In all studies t o 
date‚ absolute counts of eosinophils and basophils were within the normal range following administration of G-CSF. Increases in lymphocyte counts following dosing with G -CSF have been reported in some 
healthy individuals and subjects with cancer.  Daily administration of G -CSF has been shown in a 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 23 of 74 
 
 randomized Phase III trial to be safe and effective in children and adults with severe chronic neutropenia, 
resulting in sustained increases in the neutrophil count and decreases in infection-related morbidity.( 40T24 40T) 
In particular‚ daily treatment with G -CSF led to significant beneficial changes in the incidence and 
duration of infection‚ fever‚ antibiotic use‚ and oropharyngeal ulcers  in this setting.(24) The lower 
incidence and duration of infections was associated with decreased episodes of hospitalization, diarrhea‚ nausea‚ fatigue‚ and sore throat. In that study, the G- CSF dose was adjusted to maintain a median ANC 
between 1500  and 10‚000 cells/mm
P3
P. Overall‚ response to G-CSF was observed in 1 to 2 weeks. The 
median ANC after 5 months of G-CSF therapy was 7460/mm P3
P (range, 30/mm P3 
Pto 30‚880/mm P3
P).  
 Mild -to-moderate bone pain was reported in approximately 33% of subjects with severe chronic 
neutropenia  treated with G-CSF in clinical trials. (see 
40TAppendix C 40T) This symptom was readily controlled 
with non- narcotic analgesics. Generalized musculoskeletal pain was also noted in a higher frequency of 
subjects treated with G-CSF. Palpable splenomegaly was observed in approximately 30% of subjects. 
Abdominal or flank pain was observed infrequently, and thrombocytopenia (<50‚000/mm P3
P) was noted in 
12% of subjects with palpable spleens. Fewer than 3% of all subjects underwent splenect omy‚ and most 
of these had a pre-study history of splenomegaly. Fewer than 6% of subjects had thrombocytopenia during G -CSF therapy‚ most of whom had a pre -existing history of the condition. Thrombocytopenia was 
managed by discontinuing or reducing the dose of G -CSF . An additional 5% of subjects had platelet 
counts between 50‚000/mm
P3
P and 100‚000/mm P3
P, with no associated serious hemorrhagic sequelae. 
Epistaxis was noted in 15% of subject s treated with G- CSF‚ which was associated with thrombocytopenia 
in 2%  of the subjects. Anemia was reported in approximately 10% of subjects‚ but, in most cases, it 
appeared to be related to frequent diagnostic phlebotomy‚ chronic illness, or concomitant medications. Other AEs infrequently observed and possibly related to G-CSF therapy were injection site reaction‚ rash‚ hepatomegaly‚ arthralgia‚ osteoporosis‚ cutaneous vasculitis‚ hematuria/proteinuria‚ alopecia‚ and 
exacerbation of some pre-existing skin disorders (e.g.‚ psoriasis). Cytogenetic abnormalities, 
transformation  to myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML) have been 
observed in subjects treated with G-CSF for severe chronic neutropenia.  
 
As of 31 December 1997, data have become available from a post marketing surveillance study of 531 
subjects with severe chronic neutropenia who had an average follow-up of 4 years. Based on analysis of 
these data, the risk of developing MDS and AML appears to be confined to the subset of subjects with congenital neutropenia. A life -table analysis of these data revealed that the cumulative risk of developing 
AML or MDS by the end of the 8
Pth
P year of treatment with G-CSF in subjects with congenital neutropenia 
was 16.5%, which represents an annual rate of approximately 2%. Cytogenetic abnormalities, most common ly involving chromosome 7, have been reported in subjects treated with G-CSF who had 
previously documented normal cytogenetics. It is unknown whether the development of cytogenetic abnormalities, MDS, or AML is related to chronic daily administration of G -CSF or to the natural history 
of congenital neutropenia. It is also unknown if the rate of conversion in subjects who have not received G-CSF is different from that of individuals who have received it. Routine monitoring through regular complete blood coun t (CBC) is recommended in all subjects with severe chronic neutropenia.  
1.4 Scientific Rationale  and Clinical Justification 
Published evidence and the package insert of G-CSF suggest that long  term, high dose G -CSF therapy 
may be associated with the development of leukemia and myelodysplasia in SCN patient s.(
40T36 40T) Whether 
or not this would occur in WHIM S patients is currently unknown, but is one reason to consider alternative 
therapies.  In addition, patients have been described who due to G -CSF receptor mutations or the 
development of anti -G-CSF antibodies fail to respond to G-CSF with an increased ANC. ( 40T37 40T)  In 
addition, our anecdotal experie nce is that WHIM S patients experience severe bone pain with the normal 
dosing of G -CSF perhaps due to their increased retention of mature neutrophils in the marrow 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 24 of 74 
 
 (myelokathexis). Lastly, G -CSF is not an effective treatment for warts, the signature infect ion in WHIMS , 
which might be better addressed with mechanism -based therapy such as plerixafor .   
 
Our Phase 1  study  has provided preliminary evidence that low dose plerixafor b.i.d. is safe and effective 
over 6 months in mobilizing leukocytes to the blood, reducing infection frequency (Figure 1) and 
reducing wart burden; however, thi s stud y was not designed, controlled  or powered to establish efficacy 
of plerixafor treatment for the main clinical endpoints  in the disease (recurrent infections and warts) or to 
compare its efficacy  to G-CSF, the FDA approved  therapy  for SCN .(5)  
1.5 Preliminary Report of Unexpected Adverse Events in this Study  
As of May 2017, sixteen  subjects have been randomized  in this study of which  nine have received at least 
some of both study drugs .  
1.5.1 An Incident of a N ew Psoriasis-like R ash 
A subject experienced a worsening rash (psoriasis-like ) beginning a week after commencing the 1 Pst
P study 
drug and the symptoms resolved after switching to the alternate study drug  and topical  steroid treatment.  
1.5.2 Joint Pain (Arthralgia) and a n Incident of Reactive Arthritis  
Some  subjects with a prior history of  joint pain (arthralgia  or arthritis ) prior to  enrollment experience  a 
recurrence or worsening of their symptoms  with G -CSF and/or with the study drug(s) .  However, one 
subject  who had no prior history of joint pain or G-CSF treatment, experienced pain and swelling in his 
wrist, hands, and knees and had  to be  discontinued from both study drugs and treated with oral steroids. 
Soon after the pain began , the subject tested positive for urethral chlamydia  which causes reactive 
arthritis .  Thus it may be that the subject’s symptoms were exacerbated by the increased circulating 
neutrophil levels  caused by both drugs . 
 
  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 25 of 74 
 
  
 
 
 
Figure 1 :  Plerixafor May Reduce Infection Incidence in Patients with WHIMS. 
The data for each patient are presented in separate columns. Each infection is represented as a  
dot and plotted by the month it occurred in relation to the start of plerixafor therapy. The time on 
plerixafor is bounded by the red box. Note that data for P2 were unavailable for the 12 month period marked by the black box. For P3, the hatched box represents a gap in plerixafor administration for the purpose of clinical care.  G- CSF was administered to patients P1  and P2  
both before and after plerixafor treatm ent, whereas P3 received G- CSF for ~1 month after 
plerixafor.
 
  

Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 26 of 74 
 
 2 STUDY OBJECTIVES  
2.1 Primary Objective  
Compare the severity of infection during treatment with plerixafor and G -CSF. 
2.2 Secondary  Objectives 
1) Compare component measures of infections.  
2) Measure the control of warts with plerixafor  versus G-CSF. 
3) Demonstrate the safety of plerixafor  and G -CSF as long -term therapy . 
4) Compare the symptoms of chronic infections.  
5) Compare q uality of life (QOL) . 
6) Compare drug tolerability  and subject  drug preference. 
7) Compare the increase of leukocyte levels from baseline.  
2.3 Exploratory Objectives 
Measure type, location, and cause of infections.  
3 STUDY DESIGN 
3.1 Description of the Study Design  
This is a  Phase III, double -blind ed, randomized, crossover study evaluating  plerixafor  SQ b.i.d. versus  G-
CSF SQ  b.i.d. in children and adults 10 to 75 years of age  with a clinical dia gnosis of WHIMS , with a 
history of recurrent  infection s and a non -synonymous mutation in the C -tail of CXCR4 . Subjects who are 
pregnant  or have a history of  hematopoietic canc er or life threatening cardiac arrhythmia are excluded.   
 Interested subjects come to the NIH-CC and sign the study consent, which  initiates the Initial Evaluation  
period of the protocol, during which eligibility criter ia are evaluated.  Eligible subjects commence this 
approximately 4-12 week  period during which unblinded b.i.d. G-CSF treatment is continued  or offered, 
if the subject is not already receiving it , and dose is adjusted if necessary  to achieve an ANC between 
500-15 00 cells/μL  of blood . Subjects start completing a daily Memory Aid  submitting to the NIH-CC 
once per  week . The Memory Aid  includes their  G-CSF treatment , any new or persistent symptoms, use of 
prophylactic antibiotics , and IVIg treatments. Subjects also report use of any other medication s, incidence  
and duration of fever , new infections, incidence &  duration of antibiotic treatments, and any 
hospitalizations. Another purpose of this evaluation period  is to ensure that subjects are able to comply  
with required  study procedures . At completion of the evaluation period, subject s are randomized to begin 
either plerixafor  or G-CSF treatment .  Subjects shall ho ld G-CSF 2 days  in advance of  commencing study 
medication . The next phase of the study is the Equilibration Period of 8 weeks, during which the blinded 
study drug dose is adjusted for a target  ANC of 500-1500 cells/μL  with the ANC count  measured  
approximately every 2 weeks at a subject’s local medical facility . After this, the study drug dose is 
continued for 52 weeks, during which the dose may be adjusted to maintain the ANC between approximately 500-7500 cells/μL .  Also, in this treatment period  clinical events are counted and subjects 
visit the NIH-CC approximately every 4 months for a comprehensive assessment of chronic infections, 
warts and immune status. Between NIH-CC visits, subject s visit their local medical facility or local 
provider approximately midway between NIH-CC visits  to have blood drawn for CBC/ANC prior to the 
morning dose of study drug and for treatment of new or worsening infections. CBC/ANC is monitored at the NIH-CC for safety and the need for additional dose adjustments as determined by the Principal 
Investigator and applied by the unblinded independent pharmacist . Subjects unable to tolerate a study 
drug will  be switched to the alternate study agent  according to rules specified below in the Statistics 
(section 14).  
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 27 of 74 
 
 After completing the 1 Pst
P year of treatmen t, there is a 2-day  washout period before a subject  crosses over to 
the alternate study drug for  the 2 Pnd
P year of treatment that is again preceded  by an 8-week  Equilibration 
period. After completing  the 2 Pnd
P treatment, there is a 2-day  washout period, after which subject s are 
offered the opportunity to restart G- CSF therapy.  There is then a 1-month G-CSF Equilibration  and 
subjects continue to maintain their diaries  and to visit their local medical facility for blood draws 
approximately every two weeks. A study completion  visit at the NIH-CC occurs approximately 5 to 6 
months after the end of the second year of treatment. 
3.2 Study Endpoints 
3.2.1 Primary Endpoint 
The primary endpoint is infection severity, which is measured as a composite of multiple weighted 
parameters according to rules defined in 40TAppendix D 40T.  
3.2.2 Secondary Endpoints  
1) Component measures of infections ; incidence and duration of infections, fevers, antibiotic treatments, 
and hospitalization . 
2) Control of warts as defined by at least a 50% reduction in numbers, areas or size of existing warts and 
by the number of  new warts. 
3) Blood count and immunological param eters.  
4) Clinical measures of chronic i nfections.  
5) Treatment side effects,  
6) Quality of life scores.  
7) Treatment preference.  
3.2.3 Exploratory Endpoint  
Identify causative organisms and locations of infections in WHIM S subjects.  
4 STUDY POPULATION 
4.1 Subject Selection and Recruitment Plan  
The study is open to patients  with WHIMS from 10 -75 years of age who may benefit from the study’s 
proposed treatments. WHIMS is a rare genetic disease with approximately 60 patients identified as of 
2014 worldwide in the medical literature . We began seeing  WHIM S patients  in 2006, and as of May, 
2014 have a cohort of 24 patients , with 50% of these patients  accrued in 2012 and 2013. Sixteen  of these 
24 patients meet the eligibility criteria  for this protocol, which is powered for 20 patients to finish the 
protocol. Additional potential recruits for this study include patients referred by clinical researchers at 
NIH, by academic institutions worldwide, and by local  health care providers, as well as patient self-
referrals. A recruitment letter may be sent to relevant health providers to stimulate accrual.   The study 
will also be listed in ClinicalTrials.gov.  We expect to screen 30 patients (accrual ceiling ) in order to 
enroll and randomize 20 patients.  
4.2  Inclusion Criteria  
Subjects are eligible to enter the study if they meet all of the following criteria: 
1)  Age > 10 and <75 years. 
2) Heterozygous mutation in the C -tail of CXCR4 in addition to  a clinical diagnosis of WHIMS.  
3) Documented neutropenia with a baseline ANC below 1500 cells/μL  of blood. 
4) History  of severe and/or recurrent infection s. 
5) Willingness to interrupt G -CSF medication , 2 days  prior to study drug injection.  
6) Must have a local  medical provider for medical management.  
7) Must be willing to provide blood, plasma, serum, and DNA samples for storage. 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 28 of 74 
 
 8) All study subjects must agree not to become pregnant or impregnate a female.  Women of 
childbearing potential must  agree to take appropriate steps to avoid becom ing pregnant for the  
duration of the study. Participants in whom pregnancy is biologica lly possible must  use at least 2 
study approved methods o f contraception , one  of which must be a barrier method , and must continue 
contraception until 5 months after stopping the study drug:   
• Male or female condoms  with a spermicide, 
• Diaphragm or cervical cap with spermicide, 
• Intrauterine device, 
• Contraceptive pills or patch, Norplant, Depo-Provera or o ther FDA-approved contraceptive,  
• Male partner with vasectomy and documen ted aspermatogenic sterility.  
9) Willingness to comply with the study medications, visits, and procedures, a s deemed necessary by the 
principal investigator  (PI).  
4.3 Exclusion Criteria  
If any of the following exclusion criteria are met, a subject will not be enrolled in this study:  
1) Neutropenia due to maturation defects in the myeloid lineage or a type of neutropenia, which in the investigator’s opinion, is unlikely to improve from the medication administered in this study.  
2) Pregnant or breast-feeding  women.  
3) Known hypersensitivity  to plerixafor, G-CSF, or any components of the products.  
4) Predisposition to or history of life-threatening cardiac arrhythmia. 
5) Requiring dialysis or having markedly impaired renal function with a Creatinine Clearance ( CrCl) 
<15 mL/min  (
40TAppendix E 40T). 
6) Condition that in the investigator’s opinion places a  subject  at undue risk by participating in the 
study . 
4.4 Justification for Exclusion of Pregnant or Breast Feeding Women  
Pregnant women are excluded from this study because the effects of plerixafor  on the developing human 
fetus are unknown with the potential for teratogenic or abortifacient effects. Lactating women are excluded  because plerixafor  may be excreted in the breast milk and co uld be potentially harmf ul to breast -
fed infants. Women of childbearing pote ntial must have a negative pr egnancy test prior to receiving
P 
Pplerixafor .   
4.5 Justification for Exclusion of Children < 10 Years of Age   
Subjects younger than 10 years of age will be excluded from the study. Altho ugh WHIMS  is a rare 
congenital immu nodeficiency disorder that affects all age groups, plerixafor  has known effects on fetal 
development in animal models .(8,32,38)   These are related to early localization of cells during fetal 
development ; therefore, we feel that age 10 provides a wide safety window for completion of early 
development and allows us to treat children who may have the most to gain from this treatment in the 
future.  Children as young as 2 months  of age have been treated with single high dose (0.24 mg/kg/d) 
plerixafor  for stem cell mobilization without serious side effects and chronic G-CSF use is safe in 
children. ( 40T39,40 40T)   
5 STUDY AGENT AND INTERVENTIONS  
5.1 Drug Acquisition 
5.1.1 Plerixafor : Provided by Manufacturer  
Plerixafor  is FDA-approved for hematopoietic stem cell mobilization in cancer  and is the study drug. It is 
manufactured  by Genzyme/Sanofi Corp., Cambridge, MA , USA. The manufacturer supplies the drug , 
which is investigational in this study, a t no cost .  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 29 of 74 
 
 5.1.2 G-CSF : Obtained Commercially  
G-CSF is an FDA-approved drug manufactured by Amge n and is the comparator drug in this study 
because it  is FDA-approved for the treatment of SCN.   Drug will be sourced commercially and purchased 
per the NIH-CC policy.  
5.2 Disposition and Dispensation 
The study drug and the comparator drug are dispensed through the NIH-CC ’s pharmacy.  
5.2.1 Form ulation, Packaging, and Labeling  
5.2.1.1  Plerixafor  Packaging from M anufacturer   
Plerixafor  injection  is a sterile, preservative-free, clear, and colorless to pale yellow isotonic solution for 
subcutaneous injection. Each mL of the sterile solution contains 20 mg of plerixafor . Each single -use vial 
is filled to deliver 1.2 mL of the sterile s olution conta ining 24 mg of plerixafor  and 5.9 mg of sodium 
chloride in water for injection . Storage at room temperature is recommended at 25 °C (77°F) with 
excursions from 15° C-30° C (59°F - 86°F).  
5.2.1.2  Plerixafor  Repackaging for Study and/or Shipment to Study Participants  
Plerixafor  vials from the manufacturer will be repackaged by Integrity Bio, Inc  into pre-set low-dose 
volumes between 0.01-0. 20 mL in sterile syringes for subject  self-injection. The syringe provided to the 
subject  will contain a  dose rang ing between  0.01-0.04  mg/kg. The upper limit dose of 0.04 mg/kg in this 
study is low compared to the FDA-approved dose for HSC mobilization (0.24 mg/kg)  and was set at this 
level because our treatment goal is to reduce CXCR4 signaling to normal from 2X normal, the typical 
level for WHIM S variants of CXCR4, not to zero.  Syringes will be shipped  periodically to the subject 
who will store them at refrigeration temperature until injected . 
5.2.1.3  G-CSF Packaging from Manufacturer  
G-CSF is a sterile‚ clear‚ colorless‚ preservative-free liquid for parenteral  administration containing 
filgrastim at a specific activity of 1.0 ± 0.6 x 10 P8
P U/mg (as measured by a cell mitogenesis assay). The 
product is available in single -use vials and  prefill ed syringes. The single-use vials contain either 300 µg  
or 480  µg  filgrastim at a fill volume of 1.0 mL or 1.6 mL respectively.  Refrigerated storage is 
recommended at 2 °C - 8°C (36°F - 46°F), but vials  can be left at room temperature for up to 24 hours.  
Drug should  not be exposed to direct sunlight.  
5.2.1.4  G-CSF Re packaging for  Study and/or Shipment to Study Participants  
G-CSF vials from the manufacturer will be repackaged  by Integrity Bio, Inc  into pre-set volumes of 
between 0.0 1-0.65 mL in sterile syringes for subject  self-injection . The syringe and dose provided to a 
subject  will range between  0.01-2. 0 µg/kg. If randomized to the plerixafor  arm, the dose may be 
temporarily reduced during the transition to accommodate potential residual synergistic effects of the 
drugs between the treatment arms. Syringes will be shipped  periodically to the subject, who will store 
them at refrigeration temperature until injected. 
5.2.2 Labeling of Study Drug  
Sy
ringes containing the r epackaged  plerixafor  or G-CSF shall be labeled per NIH Pharmacy  policy. A n 
investigational use statement (“Caution: New Drug – Limited by Federal [US A] Law to Investigational 
Use”)  will also be labeled.  
5.3 Study Agent Storage and Stability 
Study Drug will be repackaged  from the manufacturer package to the  study drug configuration prior to 
shipment  and stored by the subject s at refrigerator temperature until use. The NIH verified that plerixafor 
is stable when stored in syringes at room or refrigerated temperatures for at least 6 months . Refer to the 
package inserts ( 40TAppendix B 40T & 40TAppendix C 40T) and the abstract from the American Association of 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 30 of 74 
 
 Pharmaceutical Scientists conference (
40Thttp://abstracts.aaps.org/Verify/aaps2013/postersubmissions/T2294.pdf 40T).  
5.3.1 Storage at NIH -CC 
Manufacturer -packaged drugs will be stored as indicated by the manufacturer until repackaging into 
syringes. Repackaged drug syringes will be tested for sterility  and stability, and  stored at  refrigerator 
temperature and shipped to the subject  home address on a periodic basis with appropriate packaging to 
prevent ext remes of temperature.  
5.3.2 Shipment  to Pa rticipants'  Home  
Subjects receive their study dr ug approxima tely once a month or as required. Shipments are prepared by 
the NIH Pharmacy  and sent via a rapid courier  or provided to subjects on their visits to the NIH-CC.  
5.4 Study Agent Preparation and Administration 
5.4.1 Subject Preparation  and Self-Injection  
Subjects self -administer the study drug subcutaneously every 12 hours at about the same time each day .  
5.4.2 Subject Memory Aid: Injection Site, Injection Volume, Adverse React ions 
Participants are asked to record the quantity injected, the site of injection, and any adverse reaction from 
the injection  (see 40TAppendix F 40T). Subject s are instructed to seek medical attention and  inform study staff or 
the NIH-CC of any adverse events that are life threatening, require immediate medical attention, or limit 
their ability for  self-care.  
5.5 Dose-A djustment  and Therapeutic Schedule  
The study drug dose is adjusted based on the subject’s Absolute Neutrophil Count  (ANC)  to maintain the 
pre-morning dose  ANC count at approximately  between  500-1 500 cells/μL  during the Equilibration 
period. Consideration of concurrent infection or other factors that might increase the ANC will be 
factored into ongoing clinical decisions to adjust the study medication dose.  Blinding will be maintained by having the PI or designee make  these decisions for both drugs without knowing which drug the subject  
is currently receiving and then having an independent pharmacist who is un-blinded select the drug, dose, and shipment based on the subject ’s randomization.  
5.6 Study Product Accountability Procedures  
5.6.1 Plerixafor  
The PI is responsible for ordering,  receipt, and return of  plerixafor  from /to the manufacturer.  NIH-CC’s  
pharmacy is responsible for storing , repackaging,  labeling , and shipping plerixafor  to the subject .  
5.6.2 G-CSF  
NIH-CC’s  pharmacy is responsible for sourcing and order ing G-CSF from suppliers and for repackag ing, 
labeling , and shipping G-CSF to the subject .   
6 STUDY SCHEDUL E AND ACTIVITIES  
A schedule of procedures and evaluation  for the study is shown in  40TAppendix A 40T. 
6.1 Recruitment   
Candidates are interviewed to confirm their diagnosis of WHIMS  and provided a copy of the study’s 
Informed Consent . A history of recurrent infections and neutropenia , documented CXCR4 muta tion, or a 
newly identified mutation made by analyzing specimens obtained from the subject are required to 
determine eligibility.  Subject s interested in the study are sched uled for a screening visit at NIH-CC.  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 31 of 74 
 
 6.2 Screening   
Subjects who have reviewed and signed the informed consent undergo the following procedures . 
6.2.1 Labs and Procedures  
After reviewing and signing the Informed Consent,  subject s undergo the following procedures : 
• Pregnancy test for women of childbearing potential.  
• Viral Screen: HIV,  HTLV -1 and 2, Hepatitis  B and C. 
• CBC with diff, Chemistries (Acute Care Panel, Creatine Kinase, Hepatic Panel, Mineral Panel, 
Total Protein, Lactate Dehydrogenase, Uric Acid), erythrocyte sedimentation rate (ESR ). 
• Prothrombin time (PT), partial thromboplastin time (PTT), Vitamin B -12 & Folate, and Urinalysis. 
• Echocardiogram  (within the last 5 years for adult ) must be reviewed and approved by the PI.  
• EKG.  
6.2.2 Assessment of Overall Health  
The following procedures are required to assess the subject’s overall health and safety in the study:  
• Weight.  
• Vital signs  (temperature, heart rate, and blood pressure).  
• Medical History  including history of infections and warts.   
• Medication History  including allergies, concomitant medication s, IVIg & G -CSF treatments, and 
prophylactic antibiotics. 
• Contraception counseling as appropriate.  
• Physical Exam . 
• Encourage subjects and their local providers to contact the study  coordinator and PI at the onset 
(or suspected onset) of an infection.  
6.3 Initial Evaluation  and Baseline Assessment  Period 
It is important to assess and document a subject’s health  and ensure they are trained and prepared prior to 
commencing the first study dose. This Initial Evaluation and Baseline Assessment  period is targeted  to be 
about 2 to 20 weeks or the length of time  a subject requires being trained and stable on their low -dose G-
CSF self-injections and able  to visit the NI H-CC to  commence the  first study dose  (Section 6.4). 
Procedures for baseline assessment may be completed  anytime prior to the first dose, furthermore some 
labs may be drawn and analyzed at the  subject’s local medical facility  (Section 6.3.12 ). 
6.3.1 Measurement of Immunological Markers  
The following procedures are performed to assess the subject’s immunological markers:  
• Quantitative Immunoglobulins 
• Leukocyte Phenotyping  
• Antibody levels for Diphtheria and Tetanus.  
6.3.2 Evaluation s: Dermatology, GYN, Dentistry, ENT, Audiology , and Clinical Photography  
Due to the prevalence of infections and  the risk of  HPV in patients with WHIMS, dermatologic, 
gynecologic, dental, ENT, and audiology evaluations , and photographs of infections and warts on the 
body surface,  will be arranged  for subjects prior to commencing their  first study treatment, and at the end 
of each their study drug treatments periods. These evaluations are not mandatory; a subject may refuse to 
participate in any of the assessments. These evaluations are not meant to replace care provi ded by a  
subject’s local provider(s).  
6.3.3 Additional Evaluations if Clinically Indicated (e.g. PFT and CT of Chest and Sinus)  
Some of our WHIMS patients experience frequent respiratory infections some of which result in bronchiectasis and may be debilitating. For these subjects, pulmonary function tests (PFT), sputum 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 32 of 74 
 
 cultures, CT or X -ray of the chest and sinus, as well as a pulmonary consult with possible bronchoscopy 
may be arranged to treat and evaluate the status of their infections. These evaluations are n ot mandatory; a 
subject may refuse to participate in any of the assessments.  
6.3.4 Baseline Measure of Bone Density and Spleen Size  
• Dual -energy x -ray absorptiometry (DEXA)  scan. 
• Ultrasonography of the spleen.  
6.3.5 Research  Blood  
Research blood  will be collected as required and  may include the following:  ~10 mL of EDTA anti-
coagulated blood (1 purple top), ~10 mL of serum (1 tiger top), and 30-60 mL of heparinized blood (3-6 
green tops).  The blood will be collected for various purposes, including DNA/RNA isolation, EBV-
transformed cell line creation, serum/plasma storage, flow cytometry , cytokine measurements, and drug 
levels.  
6.3.6 Wart and/or Skin B iopsy  (optional)   
Wart and or skin biopsies may be requested for diagnosis and research from subjects but will be optional. 
An experienced provider  will perform the procedure. Local anesthetics will be used for the biopsy site; no 
conscious sedation or general anesthesia will be given. The risks of skin/ wart biopsy include local pain, 
bleeding, infection, and the potential for scar and keloid formation. Antibiotics and oral analgesics will be 
used to manage pain and infection. The histologic response to plerixafor  offers generalizable knowledge 
about the pathophysiology and treatment of this condition. 
6.3.7 Bone Marrow Biopsy  (optional)   
Subjects will have the option of having bone marrow biopsy/aspiration done for research purposes, which could be done either as out patient  or inpatient. L ocal anesthetics will be used for the biopsy site and IV 
conscious sedation may be offered to subject s for comfort; these agents may result in transient local 
discomfort initially and occasionally be associated with allergic reactions. General anesthesia will only be 
given if the participant is admitted for the procedure. The primary risks of bone marrow biopsy include 
local pain, bleeding, and infection. Antibiotics and oral analgesics will be used to manage pain and infection  if necessary . 
6.3.8 Quality of Life Assessment of Period Prior to the Study  
Subjects will participate in the quality of life  surveys ( Section 7.9) with the first survey conducted  early in 
the Initial Evaluation and Baseline Assessment period, after a subject has been screened, in order to 
reflect their experience prior to interventions caused by this study.  
6.3.9 IVIg and Prophylactic Antibiotics  
Subjects on IVIg and prophylactic antibiotics prior to enrollment maintain their treatments, as clinically 
indicated, throughout the study. Though unlikely, it is also possible that subject s may be initiated on these 
treatments during the study if clinically indicated. A subject’s use of IVIg and prophylactic antibiotics 
will be tracked in the subject Memory Aid  (Section 6.3.12). 
6.3.10  Determin ing a  Minimum Effective Dose for G -CSF  
In the US, the FDA-approved treatment for SCN is G- CSF and we expect many of the WHIM S subjects 
enrolled in this study to be on daily or every other day treatment with G-CSF prior to enrollment. For this 
study, we need to determine the Minimum Effective Dose (MED) of  b.i.d G-CSF injection to achieve an 
ANC of  500-1 500 cells/μL. Enrollees , not on b.i.d G-CSF or with an ANC less than the lower limit of the 
target ANC range will have G-CSF initiated or adjusted  in this period prior to being randomized.   
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 33 of 74 
 
 6.3.11  Preparing  for Study Drug Shipment s and Study Drug Administration at Home  
Subjects will be  trained on receiving, storage, preparation, and self-administration of the  
study/comparator drugs . These procedures are reviewed and customized as necessary  for each subject  at 
their screening visit.  To verify the practicability of these  procedures, a medication  kit containing the 
comparator drug (G -CSF) may be shipped to the subject  in this period.  
6.3.12  Training and Practice for  Submissions of Completed Subject  Memory Aid  
During the initial evaluation and baseline assessment period, subjects have ample time to practice and become proficient at completing and submitting the ir clinical Memory Aid  (Sections 7.4-7.6). The 
information collected will assist in monitoring  a sub ject’s response to b.i.d G-CSF (S ection 6.3.10) and 
their proficiency at completing the Memory Aid . Subjects will not be randomized to commence study 
treatment unless they demonstrate two successful submissions and express confidence at completing the Memory Aid .  
6.3.13  Select a  Local Medical Facility  for Blood Draws at a Subject’s Home Locale 
Subjects requir e access to a local medical facility  so that we can  monitor their response , in between visits 
to the NIH-CC, to home administration of  G-CS F or plerixafor.  Labs from these facilities will be 
requested  during initial e valuation to determine the optimum dose for  b.i.d G-CSF (S ection 6.3.10) , 
during  equilibration  to adjust their study dose (Section 6.5.1), and during treatment  to ensure that their 
response to the study drug dose remains optimum (Section 6.6.2 ). We will work with each subject to 
ensure that  a local medical facility  is available for these purposes and all required study procedures are 
paid by the NIH.  
6.4 Randomization and Initiation of the First Study Dose  
After completing  their evaluation and baseline assessment ( Section 6.3), subjects are random ized to start 
with either plerixafor or G -CSF for the first year to be followed by the alternate drug for the 2
Pnd
P year. The 
NIH Pharmacy  will conduct randomization and neither the subjects nor study staff  will be aware of  which 
study drug a subject  is assigned .  
6.4.1 Washout Period P rior to the First Study/Comparator Dose (at least 2 days prior to 1st dose ) 
All b aseline assessments of infection  and warts shall  be completed prior to a subject  receiving their first 
study /comparator drug injection. Subjects  withh old their G-CSF or study/comparator drug injection  at 
least 2 days prior to  the first day of the study /comparator drug injection (Day 0 ).  
6.4.2 Assess m ent of Overall Health (within 2 days prior to the 1st dose)  
A clinical assessment similar to what was conducted at baseline (S ection 6.2.2 ) should be repeated within 
2 days prior to commencing the first study dose.  
6.4.3 Confirm Study Drug Shipment/Injection, Memory Aid , Local Labs, and Reporting 
Infections  
Review and confirm with the subject the processes established for receiv ing, stor ing, or administering  the 
study drug, complet ing and submitting the Memory Aid , and  obtaining blood draws at their local medical 
facility . Review and confirm process for reporting infections, diagnosis, and forwarding the information 
from th eir local provider.  
6.4.4 Lab Draw Prior to Injection of the 1st Study/Comparator Dose  
• CBC with diff, Chemistries (Acute Care Panel, Creatine Kinase, Hepatic Panel, Mineral Panel, 
Total Protein, Lactate Dehydrogenase, Uric Acid), erythrocyte sedimentation rate (ESR ). 
• Quantitative Immunoglobulins   
• Leukocyte Phenotyping  
• Pregnancy test for women of childbearing potential  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 34 of 74 
 
 • Research Blood . 
6.4.5 Day of the First Study/Comparator Dose  (Day 0) 
The subject  administers the morning dose  at NIH-CC while being observed by research personnel to 
confirm that the subject  is proficient with  self-administered  subcutaneous (SQ) injection .  
6.4.5.1  Prior  to Injecti on 
• Orthostatic  measurements ( i.e. pulse and  blood pressure  taken in the supine, sitting, standing , 
position approximately 2 minutes apart ) within 1 hour  prior to  study drug injection.  
• Labs: CBC with diff , chemistries, and ESR  (optional if previous labs are within 24h).  
• Research Blood  
6.4.5.2  After Study Drug Injecti on 
• Orthostatic measurements 60 m in (+/- 20 min) after study drug injection.  
6.4.5.3  Procedures P rior to Leaving NIH -CC 
• Subjects ar e supplied with study drug kit and a supply of the study/comparator drug.  
• Counse l subject s with symptomatic or measured orthostasis (decrease in blood pressure > 20 mm 
Hg systolic or increase in pulse >20 /min) to exercise additional caution with home dosing.  
• Confirm the schedule and procedure for CBC blood draws at the subject’s local medical facility.  
• Confirm p rocedures for subject  receipt of study /comparator drug, storage, and administration . 
• Confirm procedures for subject submission of reports on newly diagnosed infections and 
treatments by their local provider. Encourage subjects to contact the study coordinator or PI at the 
onset (or suspicion) of an infection. 
• Confirm Subject Memory Aid : completion, schedule, and method of submission to NIH-CC. 
6.5 Equilibration Period for the Treatment  (8 weeks) 
After administering the initial study dose at NIH-CC subject s continue injecting the study/comparator 
medication at home. The first  8 weeks  of injection is  considered the  Equilibration  period with  ANC 
measured  every 2 weeks (+/- 7 days)  at the subject ’s local medical facility . 
6.5.1 Blood Draws at Subject’s Local Medica l Facility  Every 2 Weeks 
Subjects visit their local medical facility every 2 weeks (+/- 7 days)  for blood draws prior to the morning 
dose. 
6.5.2 Dose May be Adjusted  to Maintain ANC Between 500-1 500 cells/μL  
ANC readings are reviewed at the NIH-CC and the study drug dose may be increased for ANC < 500  
cells/ µL and decreased for ANC>1 500 cells/µL . However, any decision to adjust must take into 
consideration a subject’s  clinical course and status. D ose changes are impleme nted at the next scheduled  
shipment of study/comparator drug to the subject .  
6.6 Treatment Period (52 weeks) 
At c
ompletion of the Equilibration period, subject s commence a 52 week  treatment  period with a constant 
dose unless ANC <500  cells/µL, in which case the dose may be increased, or ANC > 7500 cells/µL absent 
concomitant infections that may elevate the ANC , in which case the dose will be decreased. Subjects visit 
NIH-CC at the start of treatment and  every 4  months  (+/- 31 days)  of treatment for a comprehensive 
assessment of chronic infections, warts and immune status. Between NIH-CC visits, subject s visit their 
local facility or provider at least once, midway between NIH-CC visits, to have blood drawn for 
CBC/ANC or  as needed for treatment of new or worsening infections. The 1 Pst
P treatment period ends  with 
the End of Treatment (EOT) visit. 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 35 of 74 
 
 6.6.1 Assessments at  NIH -CC Every 4 Months  
Subjects visit NIH-CC every 4 months  (+/- 31 days)  after start of the T reatment  Period  for a 
comprehensive assessment of their health and safety, pregnancy status if applicable, immun ological 
markers, chronic infections, and warts.  
6.6.1.1  Labs  
• Pregnancy test for women of childbearing potential.  
• CBC with diff, Chemistries (Acute Care Panel, Creatine Kinase, Hepatic Panel, Mineral Panel, 
Total Protein, Lactate Dehydrogenase, Uric Acid), erythrocyte sedimentation rate (ESR ). 
6.6.1.2  Assessment of Overall Health and Safety  
A clinical assessment similar to what was conducted at baseline (S ection 6.2.2 ) should be repeated at each 
4-month visit to the NIH -CC.  
6.6.1.3  Measurement  of Immu nological Markers 
The following procedures are performed to assess the subject’s immunological markers:  
• Immune Status (basic): Quantitative Immunoglobulins 
• Leukocyte  Phenotyping  
6.6.1.4  Evaluations and Consults for Assessm ent of Infections  
Subjects may  be scheduled for assessment as determined at the baseline visit or as clinically indicated by 
the PI for worsening of  infections  and/or warts, as described in Sections 6.3.2  and 6.3.3. 
6.6.1.5  Research  Blood  
As with the baseline assessment visits, research bloods may be collected at each visit to the NIH-CC 
including blood drawn at peak  - e.g. approximately 3 hours after the morning study drug injection.     
6.6.1.6  Quality of Life Assessment  
Subjects  will participate in quality of life surveys ( Section 7.9) with the first survey conducted early in the 
Initial Evaluation and Baseline Assessment period  and at each 4-month visit to the NIH -CC.  
6.6.1.7  Skin and Wart Biopsies (optional)  
As with the baseline assessment visits, skin and or wart biopsies may be proposed for research purposes.  
6.6.2 CBC w/diff , ESR, and Chemistries E very 2 Months at Subject’s Local Medical Facility  
Subjects visit their local medical facility once (at 2 months +/ - 31 days) in between their scheduled NIH-
CC visits for monitoring of their ANC and changes in blood counts (e.g. anemia or thrombocytopenia). 
Changes in kidney function and serum electrolytes ( chemistry ) and ESR (optional)  will also be requ ested 
and the results transmitted to NIH-CC. The  blood draw for the se tests should be performed prior to the 
morning dose of study drug.  
6.6.3 Visits to a Subject’s Local Provider for New or Worsening Infections  
Subjects continue visits to  their local pro vider for routine exam s and for  treatment of new or worsening 
infections . Because the study measures the frequency and severity of infections, it is important that 
subject s submit d ocumentation of infection either through a  medica l record of their visit or through their 
provider completing  a brief  form specifying  the diagnosis, treatment, and the result of  microbial cultures 
( 40TAppendix G 40T). Subjects and their local providers are encouraged to contact the study coordinator or PI at 
the onset of infection related events.  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 36 of 74 
 
 6.6.4 End of Treatment (EOT) Visit for a Study Drug  
The last visit to the NIH-CC during the treatment period constitutes the End of  Treatment Visit (EOT) 
where a subject  ceases injection of the study or comparator drug and the subject’s response to the year’s 
treatment is assessed : 
• All assessment s to measure the study drug safety and efficacy are com pleted . 
• Subject returns all unused study drug to the NIH-CC. 
In addition  to the procedures conducted at the 4 -month visits during treatment , the following procedures 
are conducted at the EOT visit:  
• EKG,  
• Dual -energy x -ray absorptiometry (DEXA)  scan, 
• Ultrasonography of the spleen , 
• Vitamin B12 and Folate, 
• Antibody levels for Diphtheria and Tetanus . 
6.7 Reverting to a  Subject’s Pre-study  Treatment 
After  completing both study treatments, subject s revert  to their pre-study treatment  regimen  and are 
offered G-CSF . Subjects continue  to submit  their diaries and  their ANC results to NIH-CC until the Study 
Completion visit. Adjustments to G-CSF dose may be made according to ANC during this phase.  Subjects of child bearing potential shall continue to maintain at least two forms of contraception.  
6.7.1 Washout Period ( 2 Days ) 
Subjects reverting back to G-CSF treatment should delay restarting G-CSF for at least two days in order 
to minimize  the possibility of drug interaction between plerixafor  and G -CSF. 
6.7.2 Monitoring the  G-CSF  Dose (1 -2 Months ) 
To accommodate potential synergistic drug interaction s between plerixafor  and G -CSF, a subject ’s initial 
G-CSF dose will be reduced and  their ANC monitored at 2-week  intervals (+/ - 7 days)  for the  first month 
and at 2-month (+/- 31 days)  intervals thereafter, or as clinically indicated.  
6.7.3 Study  Completion Visit   
The study completion visit  occurs approximately 5 to 6 months after the EOT visit of  the 2
Pnd
P treatment  
period. The assessments for this visit are described in Section 6.6.1.  
6.8 Early Completion of Treatment Due to  Unwillingness or Inability to Receive Study Agent  
If for any reason a subject  is unwilling or unable to continue receiving the study agent during the D ose 
Equilibration or Treatment periods, including  reasons such as 1) an i nability to maintain a minimum  ANC 
level considered safe, defined as ANC greater than or equal to 500  cells/ µL, 2) a r efusal to continue with 
the study agent , or 3) a Grade 3 or 4 Toxicity to the study agent,  a subject  would  terminate  that phase of 
the study and proceed to the next phase.  Data handling for patients who fail to complete both arms of the 
study is detailed in the Statistics section ( Section 14). 
7 STUDY PROCEDURES AND EVALUATIONS  
7.1 Absolute Neutrophil Count (ANC)  
A primary goal in WHIMS treatment is the correction of neutropenia. The Ab solute Neutrophil Count 
(ANC) is measured  as a compon ent of a  Comple te Blood Count (CBC) test.  Normal ly between  1500-
7500 cells/µL , most WHIMS patients without G -CSF, Granulocyte Macrophage Colony -Stimulating 
Factor ( GM-CSF), or plerixafor  treatment will have a Baseline ANC between 0-500 cells/µL .   
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 37 of 74 
 
 7.1.1 Time of Day Measurement for ANC: Prior to Study  Dose  
The ANC level is measured prior to a study dose. Since p lerixafor and G -CSF are administered twice 
daily , the ANC should be measured prior to a dose to measur e the minimu m ANC level  approximately  12 
hours after a study dos e.  
7.1.2 Target ANC during 8 week  Equilibration Period  (500  – 1500 cells/µL ) 
ANC is measured approximately every 2 weeks in this 8 -week period and the dose will be adjusted for  a 
target  ANC approximately between 500-1500  cells/µ L that  we have found to be achievable with well -
tolerated low -dose plerixafor  in our preliminary studies  of patients with WHIMS .  
7.1.2.1  Subjects with a Baseline ANC > 500  cells/µL  
Subjects will be excluded if they do not have neutropenia ( Baseline ANC >1500  cells/ µL); however, if 
they do have neutropenia,  but their baseline ANC average is greater than the target ANC=500  cells/ µL, 
then they will be given the minimal dosage of both drugs specified by the study in Section 7.1.4 ) with 
downwards adjustment possible if they exceed the maximum ANC (7500 cells/µL ). Baseline ANC is 
assessed  on at least two measurements on separate days, when a subject  is not on G -CSF, ple rixafor, or 
experiencing an acute infection.  
7.1.2.2  Subjects Unable to Attain ANC >500  cells/μL During Equilibration, Despite Maximal Dose  
The target ANC of 500 cells/ µL is accepted as safe in the medical literature.  Therefore, for participants 
whose baseline ANC is <500 cells/ µL, we will  administer up to the maximal dose  for the study (0.04 
mg/kg b.i.d. for plerixafor  or 2 µg/kg b.i.d. for G-CSF), that is needed to increase the ANC to a minimum 
of 500 cells/ µL and to maintain it at this level as a minimum.  If in the dose equilibration period a study 
subject fails to attain an ANC of 500 cells/ µL on the maximum  dose cited above, they would be declared 
a failure on that treatment, stop receiving that treatment, and commence “early” crossover and washout process for switching to the 2
Pnd
P Treatment, or if failing to respond during the 2 Pnd
P Treatment, a subject  
would terminate all study treatments, revert to their pre -study treatment regimen if appropriate or desired, 
and continue to the Study Completion Visit.  
7.1.3 Target ANC during the 52 week  Treatment Period  (500 – 7500 cells/µL) 
After completing the Equilibration period, subject s commence a 52 -week t reatment period with the  goal 
of a constant dose optimized for the subject. During the treatment period, this dose will only be increased 
for ANC <500 cells/µL  or decreased for ANC  >7500 cells/ µL, in 2 consecutive measurements on separate 
days,  absent infections that may elevate the ANC.   
7.1.4 Dose Range for Low-Dose Treatment  
The doses prescribed  in this study are significantly lower than the maximum doses that have been used in 
humans  for stem cell mobilization. The maximum current approved dosage  for plerixafor  = 0.24 
mg/kg/day  and this is given on up to 4 consecutive days for aphere sis ( 40TAppendix B 40T). SCN (most of 
which is due to ELANE mutations ) has been treated  with G-CSF= 2.3 to 40 µg/kg/ day ( 40TAppendix C 40T). 
The dose ranges in this study were selected based on our prior experience with the dosages that are 
effective in patients with WHIMS  in reaching the target biomarker window of 500<ANC<1500:  
G-CSF:  0.25 - 2 .0 µg/kg twice per day , 
Plerixafor :  0.01 - 0.04 mg/kg twice per day . 
The dose for plerixafor  will be reduced for renal impair ment . ( 40TAppendix E 40T)  
We already have experience treating 16 WHIM patients with low dose daily G-CSF for extended periods with excellent compliance. In our 6 month Phase 1 study of plerixafor in WHIMS , the drug 
was well -tolerated and compliance was excellent.  Interestingly, we observed that  the ANC declined 
more slowly than expected  after stopping plerixafor , taking 2-3 weeks to reach  the subject ’s baseline, 
and that the response to G-CSF once at baseline was greater than expected.(5)  Therefore, subject s 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 38 of 74 
 
 assigned G-CSF in the 2 Pnd
P year treatment in the present study will  be started on a lower  dose in the 
Equilibration Period  than the  optimum dose defined  during the evaluation  period. The dose will then 
be adjusted if necessary, as guided by the ANC response.   
7.2 Adjusting  the Study Dose to Meet ANC Goals  
A subject ’s dose is increased  for ANC below 500 cells/µL , and maintained for ANCs up to 1500 cells/µL 
during the  8-week E quilibration period and for  ANCs up to 7500 cells/ µL during the 52-week treatment  
period. Doses of either drug  may be reduced if the steady -state counts  exceed the upper ANC threshold s 
in the absence of an acute infection . Two sequential ANC values on diff erent days prior to the morning 
study drug dose will be used at the times indicated in the protocol to make study drug dose adjustments .  
7.2.1 Initial Study/Comparator Drug  Dose s during  Equilibration P eriod  
G-CSF - without a known history of treatment with G-CSF :  0.5 µg/kg b.i.d. 
G-CSF - with a history of G -CSF dosing :   S pecified by PI prior to randomization.  
G-CSF - after recent treatment with plerixafor   Specified by PI prior to randomization . 
Plerixafor :       0.01-0.04  mg/kg twice per day . 
7.2.2 Adjustment for ANC <50 0 cells/µL  
G-CSF:  Increas e dose to a maximum of 2.0 µg/kg b.i.d. 
Plerixafor : Increase dose to a maximum of 0.04 mg/kg b.i.d. 
7.2.3 Adjustment for ANC between 500 – 1500 cells/µL in the Equilibration Period  
G-CSF:  Maintain dose .  
Plerixafor : Maintain dose .  
7.2.4 Adjustment for ANC > 1500 cells/µL  in the Equilibration Period  
G-CSF:  The G-CSF dose may  be reduced after review of a subject’s clinical course.  
Plerixafor : The plerixafor  dose may be reduced after review of a subject’s clinical course.   
7.2.5 Adjustment for ANC > 7500 cells/µL  in the Treatment Period 
G-CSF:  G-CSF dose  may be reduced after review of a subject ’s clinical course. 
Plerixafor : The pl erixafor  dose may be reduced after review of a subject’s clinical course.  
7.3 Immune Status: Leukocyte Im munophenotypes 
Leukocyte numbers available from the CBC (ANC, etc.) will be averaged for each 1 -year treatment 
period with either the Study Drug or Comparator Drug and statistical comparison will be performed as part of the secondary endpoints.  Lymphocyte flow cytometry results (CD19+, CD4+, CD8+, etc.) will be 
averaged from the 4, 8, and 12 month visits  to the NIH-CC for each agent  and statistical comparison will 
be performed as part of the secondary endpoints . Changes in leukocyte numbers will also be analyzed by 
length of time on the Study Drug or Comparator Drug.   
7.4 Medication Compliance: Study Drug and Prophylactic Antibiotics  
7.4.1 Subject Memory Aid  
It is important to track a subject ’s compliance with the study drug, IVIg, and  prophylactic antibiotics. 
Compliance is likely to affect  a subject ’s susceptibility to infec tion.  Considering the dura tion of study 
participation, incomplete entries can be expected ; therefore,  we encourage frequent communications with 
study subjects in an effort to collect all details concerning adverse events, infections, missed doses of study agent and other concomitant medications taken.  The references to diary card have been changed to memory aid as this is more of a tool the subjects can use in addition to information gathered by the study 
team via frequent communication with subjects such as via phone calls, emails,  and phone texts,  
especially whenever a new infection, unusual side effects or a change in  medication or dose occurs.   
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 39 of 74 
 
 7.4.1.1  IVIg Treatment and Dose 
Subjects record the Date and Dose of the most recent IVIg infused.   
7.4.1.2  Record  Temperature for Fevers  
Subjects record their highest temperature for the day  if they have a fever (defined as oral temperature 
>38.3 Po
PC. Subject s are encou raged to visit their local provider if they develop a fever.  
7.4.1.3  Compliance with Prescribed Prophylactic Antibiotics  
Subjects record changes to their use of prophylactic antibiotics. 
7.5 Study Drug Side Effects and Toxicity 
7.5.1 Subject Memory Aid  
The most common side effects expected of the study drugs are listed in the Memory Aid  ( 40TAppendix F 40T) 
for subject s to rate. Subjects also have the option of  specify ing additional side effects. The rating scale 
described below is based o n CTCAE v4.0. Please note the following definitions for Activities of Daily 
Living (ADL): 
Instrumental ADL : Preparing meals, shopping, using telephone and managing money etc.  
Self-care ADL:   Bathing, dressing, feeding, u sing toilet, taking medications and not bedridden.  
7.5.1.1  Injection Site Reaction 
Subjects inje ct the study drug subcutaneously twice per day  and record the  Injection Site R eactio n defined 
as “intense adverse reaction (usually immunologic) developing at the site of an injection, for the period 
between injections.   
 Not Injected:   Subject did not inject the drug.  
1 - Tenderness Tenderness with or without associated symptoms (warmth, redness, itching).  
2 - Pain   Pain; lipodystrophy;  edema (swelling); phlebitis (inflammation of  a vein ). 
3 - Ulceration  Ulceration or necrosis; severe tissue damage; operative intervention indicated. 
4 - Life-threatening  Life-threatening consequences; urgent intervention indicated.   
7.5.1.2   Bone (Skeletal) Pain: back, arms and legs  
Subjects may complain of pain  after treatment, likely due to leu kocyte mobilization. Bone pain: marked 
deep aching or throbbing discomfort in the back, arms, and legs. Subject s rate their worst pain  for the day. 
1 - Mild   Mild pain . 
2 – Moderate Moderate pain; li miting I nstrumental ADL . 
3 - Severe  Severe pain; limiting Self -care ADL . 
7.5.1.3  Other Pain: shoulder, abdominal etc. 
The study drug may cause enlargement of the spleen, which  may result in shoulder or abdominal pain. 
Subjects should record any pain not related to bone pain. 
1 - Mild   Mild pain . 
2 - Moderate Moderate pain; limiting Instrumental ADL. 
3 - Severe  Severe pain; limiting  Self-care ADL . 
7.5.1.4  Headache 
Subjects may complain of headache, a sensation of marked discomfort in various parts of the head . 
Subjects record their worst symptoms for the day.  
1 - Mild    Mild pain.  
2 - Moderate   Moderate pain; limiting Instrumental ADL. 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 40 of 74 
 
 3 – Severe  Severe pain; limiting Self -care ADL . 
7.5.1.5  Dizziness  
Subjects may complain of dizziness - disturbing sensation of lightheadedness, unsteadiness, giddiness, 
spinning, or rocking. Subject s record their worst symptoms for the day.  
1 - Mild    Mild unsteadiness or sensation of movement.  
2 - Moderate   Moderate unsteadiness or sensation of movement; limiting Instrumental ADL.  
3 – Severe  Severe unsteadiness or sensation of movement; limiting Self -care ADL . 
7.5.1.6  Nausea  
Subjects may experience nausea - a queasy sensation or an urge to vomit - that may be related to the study 
drug. Subject s tabulate their symptoms for that day.  
1 – Mild   Loss of appeti te without alteration in eating habits . 
2 – Moderate   Oral intake decreased w/o significant weight loss, dehydration or malnutrition . 
3 – Severe  Inadequate oral caloric/fluid intake; tube feeding, TPN; hospitalization indicated. 
7.5.1.7  Vomiting  
Subjects ma y experience vomiting - a reflexive act of ejecting the contents of the stomach - that may be 
related to the study drug.  Subject s tabulate their  symptoms for the day.  
1 - 1 to 2 episodes  1-2 episodes (separated by 5 minutes) in 24 hrs.  
2 – 3 to 5 episodes  3-5 episodes (separated by 5 minutes) in 24 hrs.  
3 – 6 or more ≥6 episodes (separated by 5 minutes) in 24 hrs . 
4 – Life-threatening  Life threatening consequences, urgent intervention required. 
7.5.1.8  Diarrhea  
Subjects ma y experience diarrhea – frequent and watery bowel movement - that may be related to the 
study drug. Subject s tabulate their symptoms for  the day. 
1 – Increase <4 stools Increase of 1 -4 stools per day over baseline.  
2 – Increase 4 -6 stools   Increase of 4 -6 stools per day over baseline.  
3 – Increase >=7 stools  Increase >=7 stools per day; incontinence; hospitalization indicated.  
     Limiting Self -care ADL.  
4 – Life-threatening    Life threatening consequences, urgent intervention required. 
7.5.1.9  Subject Specifies Other Symptoms or Adverse Events. 
Subjects can specify other study drug reactions and rate t he severity for that day.  
 
1 – Mild   Mild sym ptoms; intervention not indicated (required).  
2 – Moderate Minimal, local or noninvasive  intervention indicated; limiting Instrumental AD L. 
3 – Severe  Medically significant but not immediately life -threatening.  
Hospitalization indicated, disabling; limiting Self -care ADL.  
4 – Life-threatening  Life threatening consequences; urgent intervention required.  
7.5.2 CBC, Chemistries, ESR, and Pregnancy for Women of Childbearing Potential 
In addition to ANC  and the CBC w/diff, we may request additional  labs including  blood chemistries, and 
ESR. These standard clinical tests will allow us to monitor for changes in blood counts (anemia or 
thrombocytopenia),  changes in kidney or liver function, serum electrolytes, and blood glucose.  For 
women of childbearing potential, a urine or serum pregnancy test will be conducted.  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 41 of 74 
 
 7.5.3 Splenic Enlargement  
There is a possibility of splenic enlargement  with both drugs : very rare cases of splenic rupture have  been 
reported in patients following the administration of G -CSF ( 40TAppendix C 40T) and rats given high doses of 
plerixafor  were found to have splenic enlargement  ( 40TAppendix B 40T). 
7.5.3.1  Spleen Ul trasonography  
Since WHIM S patients may develop splenomegaly  prior to therapy, a spl een u ltrasonography  will be 
performed prior  to the first study dose and at the end of each treatment period . Addition al sonograms may 
be performed at subsequent visits if clinically indicated.       
7.5.3.2  Spleen Assessment as part of Physical Examination at Research Assessment  
Assessment of the spleen will be part of the physical exam at NIH-CC visits every 4 months .  
7.5.4 Electrocardiogram  
An electrocardiogram (EKG) will be performed during screening to serve as baseline and to rule out preexisting cardiac arrhythmia. EKG will be repeated at the EOT visit for each treatment arm.  
7.5.5 Echocardiogram  
If an echocardiogram (ECHO) has not been performed in the previous 5 years on a subject or the results 
of such a test cannot be obtained, this non-invasive cardiac testing will be performed to look for congenital cardiac malformations or cardiac conditions that would predispose  a subje ct to life threatening 
arrhythmia.  
7.5.6 Dual -energy X -ray Absorptiometry (DEXA) Scans 
To monitor for the loss of bone density, dual -energy x -ray absorptiometry (DEXA) scans will be 
performed prior to the first study dose and at the end of each treatment period.   
7.6 Rate and Severity of Infections 
7.6.1 Subject Memory Aid : Symptoms of Infections  
7.6.1.1  Incidence and Severity of  Fever  
Subjects should report  symptoms of  chills or fevers and take their oral temperature as required.  The 
highest tempera ture measured that day  should be recorded. Subjects are encouraged to visit their local 
provider if they develop a fever.  
7.6.1.2  Number of  Days with Fever  
Each day a subject reports an elevated oral temperature at any time during the day above 38.3°C  is 
counted as a day with fever.  
7.6.1.3   Change in Severity of Chronic Infection  
WHIM S patients often experience ongoing chronic infections with t he type, symptom, and severity 
varying amongst the patients. We plan to identify and measure changes in the severity of these infections.   
7.6.1.4  Visits to Local Provider for Medical Exam or Treatment  
Subjects should record visits at their local facility for medical exams or treatments.  
7.6.1.5  Incidence and Duration  of Antibiotic  for Treatment  
Subjects should specify any antibiotic prescribed or taken to treat an  infection and record the m edication 
activity for that day. The duration of antibiotic use is based on the number of days from the start date to 
the end date of treatment recorded in the Memory Aid . A missed day or missed partial day is included in 
the duration.  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 42 of 74 
 
 7.6.2 Clinical Diagnosis and Treatment of Infection s 
While en rolled in the study, subject s continue visits to their local medical provide r for clinical care, as per  
their routine prior to enrollment. The diagnosis and treatment results  of their infection should be 
submitted to NIH-CC using either or both of the following methods:  
7.6.2.1  Local Provider Completes a Diagnosis and Treatment Form  (option 1)  
The local provider completes the Diagnosis and Treatment form:  
• Date of Visit,  
• Chief Complaint, Onset of Symptoms , 
• Diagnosis,  New/Chronic/Recurrent/Exacerbation ,  
• Infection: Site, Type (viral, fungal, bacterial, etc..), Suspect Causative Organism,  
• Treatment Prescribed, and  
• Results of related Laboratory Tests or Cultures, 
• Outcome of Infections (Resolved, Resolved with residual Symptoms, Ongoing) , 
• Provider will be encouraged to contact study staff. 
Localized infection sites that are contiguous will be considered as 1 single infection. A sample form that 
can be used by the study coordinator, PI, or local care provider is shown in 40TAppendix G 40T.  
7.6.2.2  Subject or Provider forwards Documents Relating to the Infection  (option 2)  
Subject obtains or requests a copy of their medical records related to the infection to be sent to NIH-CC.  
7.6.3 ENT and Audiology Evaluation at NIH -CC 
Subjects with a history of ear or sinus infections are scheduled for  Audiology and ENT  at baseline and 
completion of each  study drug treatment . Additional consults may be scheduled as medically necessary.  
7.6.4 Dental and Oral Evaluation 
Subjects are scheduled for assessment of dental caries, periodontal disease, and HPV at baseline and completion of each  study drug treatment . Additional consults  may be scheduled as medically necessary.  
7.6.5 PFT  for Subjects with Chronic Respiratory Infections 
WHIM S patients frequently suffer from repeated pulmonary infections that  result in bronchiectasis and 
chronic bronchitis.  Subjects may undergo pulmonary function tests during screening and at the end of 
each treatment period. In addition, subjects with a history of respiratory infections may be scheduled for a 
pulmonary consult at screening to optimize their therapy. Additional consults can be scheduled if needed for new or worsening infections/lung function  
7.7 Monitoring  Warts 
7.7.1 Photos of  Infections and Warts  
For subject s with warts who consent to clinical photography, a comprehensive photo set encompassing an 
overview of the external surface of the body will be taken at baseline and at the end of each treatment period, inc luding detailed photographs of the hands and feet, which are typical sites for warts in WHIM 
patients.  Detailed photos may be taken of particular warts and other types of skin infections, including infections in the anogenital areas if applicable. The photos will serve as the measure of the number and severity of infection. To ensure consistent measurements, a similar set of photos will be taken at subsequent visits to the NIH-CC. 
7.7.2 Recording the Quantity and Severity of Warts  
A case report form will be utilized to document the type, appearance, and location of the warts, 
photographs of the warts, treatments of existing warts, appearance of new warts, and representative 
warts/wart areas of interest will be quantified and tracked at each visit to the study  center . 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 43 of 74 
 
 7.7.3 Dermatolo gy Evaluation  
Subjects will be evaluated by dermatology at baseline and at the completion of each study drug. 
Additional consults may be scheduled if requested by dermatology or for new or worsening cutaneous 
infections . 
7.7.4 GU/GYN Evaluation   
Subjects will be scheduled for a genitourinary or gynecology exam at baseline and at the completion of 
each study drug. Additional exams can be scheduled if requested by GU/GYN or for new or worsening 
infections.  
7.8 Specimen Preparation, Handling , and Shipping  
As the transmission of human immunodeficiency virus ( HIV) and other blood-borne pathogens can occur 
through contact with contaminated needles, blood, and blood products, appropriate precautions will be 
employed by all personnel involved in the drawing of blood and the shipping and handling of all 
specimens for this study, as currently recommended by the Centers for Disease Control and Prevention and the NIH.  
7.9 Quality of Life (SF36 v2)  
Subjects will complete a validated Quality of Life questionnaire (SF- 36, version 2) at Baseline and at the 
4, 8, 12 month visits to NIH -CC during the treatment period. At completion of the second treatment 
period, subject s will be asked whether they prefer the first drug they received or the second.  
7.10 Request for Excess Tissue 
Tissue removed for medical indications at the NIH or elsewhere that is not required for a subject’s 
medical care and would otherwise be discarded, with the subject’s permission, may be requested  to be 
sent to the NIH for pathologic or research purpo ses. 
8 POTENTIAL RISKS AND BENEFITS  
8.1 Potential Risks  of plerixafor  
The dose for plerixafor  in this study is 0.01-0.04  mg/kg SQ twice per day is 3 to 12 times less than the 
FDA-approved and commonly prescribed dose of 0.24 mg/kg per day  when used in combination with G -
CSF for hematopoietic stem cell mobilization. The most common adverse reactions (ARs; ≥ 10%) 
associated with plerixafor  at 0.24 mg/kg/ day in combination with G -CSF administered subcutaneously  to 
subjects with cancer at doses that were over 3-12 fold higher than the dose that will be used in the current 
study include diarrhea, nausea, fatigue, injection site reactions, headache, arthralgia, dizziness, and vomiting.   
 
UInjection site reactions U: A temporary urticaria-like, pruritic, raised and erythematous lesion can occur at 
the injection site and is common with higher doses than will be used in this study. These reactions typically resolve within minutes with no treatment. Prolonged reactions if problematic will be treated with 
standard medical therapies such as topical corticosteroids, oral antihistamines, etc.  
 
Musculoskeletal Pain:  Musculoskeletal pain may affect bones, muscles, ligaments, tendons, or nerves 
and may include one or a combination of the following types of pain:  Bone Pain (deep dull pain from the 
back, legs, and arms), Joint Pain or Arthralgia (pain and/or swelling in the joints), Back Pain, and or Pain 
in the Extremities .  
  
Gastrointestinal side effects: Various side effects related to gastrointestinal function have been reported 
after doses of 0.24 mg/kg including abdominal pain, diarrhea, constipation, nausea, and vomiting, all at 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 44 of 74 
 
 higher rates than in subject s given placebo. In general, these have not resul ted in the need to stop the 
medication.  
 
Excessively high white counts (leukocytosis):  Because of the mechanism of action of this medication, it is 
expected that white blood cell counts will rise. However, normal volunteers have not risen above 25,000 cells/ µL of blood after 1 day of treatment at 0.24 mg/kg/day. The subjects likely to be enrolled in this 
study generally have low circul ating WBC and are unlikely to develop leukocytosis.  As an additional 
safety measure, we are starting participants at a low dose of study medication and can lower  it if indicated 
by a high ANC count  (>7500 cells/ µL). 
 
Thrombocytopenia and bleeding: Lower platelet counts (thrombocytopenia) have been reported with 
administration of both study /comparator  drugs , but no serious bleeding events have been reported for 
plerixafor  to date.  
 
Splenic enlargement: An increase in spleen size has been shown to occur in rats treated with plerixafor  at 
proportionately higher doses than will be used here. Although this has not been reported as causing any severe problems in humans, we will monitor for clinical signs of problems by asking subject s about left 
shoulder or left upper quadrant abdominal pain at NIH-CC visits . If these occur, the subject will be 
evaluated by medically appropriate imaging and the study drug may be stopped at the discretion of the PI.  
In addition, spleen size will be monitored by ultrasound as specified in 
40TAppendix A 40T. 
 
Cardiac Arrhythmia: In one human study, 2 HIV-infected patients developed a non -life threatening 
cardiac arrhythmia consisting of frequent premature ventricul ar contractions. ( 40T10 40T) Individuals who are at 
high risk for life threatening arrhythmia based on EKG or cardiac problems detected on ECHO or who 
have a past history of life threatening cardiac arrhythmia will be excluded from this study.  
 
Paresthesia: In one  human study, some HIV-infected patients developed some transient perioral or 
peripheral numbness that resolved with discontinuation of the drug. The patients affected were treated with doses considerably higher than will be used in this study and the probl em may have been related to 
other medications, which HIV-infected patients commonly use, or HIV itself.  
 
Exacerbation of Chronic Bronchitis /Pneumonia: One of three WHIM subject s treated with plerixafor in 
our previous 6 month Phase 1 trial developed an acute exacerbation of chronic bronchitis  and a 
pneumonia during treatment .(5)  However, this is already common in untreated WHIM S patients , so 
cannot be considered a risk of plerixafor.  WHIM patients often develop bronchiectasis as they age a s a 
result of r epeated  lung infections. This may lead to poor clearance of sputum and chronic bronchitis with 
frequent exacerbations and chronic colonization of the sputum with bacterial and fungal pathogens typical for cystic fibrosis patients,  (i.e., Pseudomonas, Stenotrophomonas, and Aspergillus ). Increased circulating 
neutrophils from either plerixafor or G-CSF could contribute to thickened sputum, which may worsen this 
chronic problem.  If subject s have chronic respiratory symptoms, sputum culture for these bacteria as well 
as tuberculosis and atypical mycobacteria will be obtained at the screening visit.  Subjects who suffer 
from this disease complication may receive pulmonary consultation and have their pulmonary treatment 
regimen optimized prior to randomization and study drug initiation. This pulmonary regimen may include drug treatments such as inhaled or nebulized beta adrenergic agonists, anticholinergic medications, hypertonic saline, prophylactic antibiotics, or DNase enzymes, and physical stimulation of the cough 
reflex with breathing devices or treatments to improve sputum clearance.  
 
Varicella Zoster Infection:  During chronic plerixafor therapy we observed reactivation of herpes zoster in 
one of three subjects. (5)  The subject  was treated with oral acyclovir and the infection resolved 
completely within days.   
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 45 of 74 
 
 8.2 Potential Risks for G -CSF 
Allergic -type Reactions:  Allergic -type reactions occurring on initial or subsequent treatment have been 
reported in <1 in 4000 of subjects trea ted with G -CSF. These have generally been characterized by 
systemic symptoms involving at least two body systems‚ most often skin (rash‚ urticaria‚ facial edema)‚ respiratory (wheezing‚ dyspnea)‚ and cardiovascular (hypotension‚ tachycardia). Some reactions occurred on initial exposure. Reactions tended to occur within the first 30 minutes after administration and appeared to occur more frequently in subjects receiving intravenous G-CSF. Rapid resolution of symptoms occurred in most cases after administrati on of antihistamines‚ steroids‚ bronchodilators‚ and/or 
epinephrine. Symptoms recurred in more than half the subjects who were rechallenged.  
 
Splenic Rupture:  Splenic rupture, including exceedingly rare fatal cases, has been reported following the 
administration of G -CSF. Individuals receiving G -CSF who report typical left upper abdominal and/or 
shoulder pain will be evaluated for an enlarged spleen or splenic rupture. In addition, spleen size will be 
monitored by ultrasound as specified in 40TAppendix A 40T. 
 
Musculoskeletal Pain:  Musculoskeletal pain may affect bones, muscles, ligaments, tendons, or nerves 
and may include one or a combination of the following types of pain:  Bone Pain (deep dull pain from the back, legs, and arms), Joint Pain or Arthralgia (pain and/or swelling in the joints), Back Pain, and or Pain in the Extremities.  
  
Acute respiratory distress syndrome (ARDS) : ARDS has been reported in patients receiving G-CSF, and 
is postulated to be secondary to an influx of neutrophils to sites of inflammation in the lungs. Subjects receiving G-CSF who develop fever, lung infiltrates, or respiratory distress should be evaluated for the 
possibility of ARDS. In the event that ARDS occurs, G-CSF should be withheld until resolution of ARDS 
or discontinued. Subjects will receive appropriate medical management for this condition.  
 
Alveolar Hemorrhage: alveolar hemorrhage manifesting as  pulmonary infiltrates and hemoptysis 
requiring hospitalization has been reported in healthy donors undergoing peripheral blood progenitor cell 
mobilization. Hemoptysis resolved with discontinuation of G -CSF.  
 
Growth Factor for Tumor : G-CSF is a growth factor that primarily stimulates neutrophils. However‚ the 
possibility that G -CSF can act as a growth factor for any tumor type cannot be excluded.  
 
Immunogenicity:  As with all therapeutic proteins, there is a potential for immunogenicity. The incidence 
of antibody development in subjects receiving G -CSF has not been adequately determined. While 
available data suggest that a small proportion of subjects developed binding antibodies to G -CSF, the 
nature and specificity of these antibodies has not been adequat ely studied. Cytopenias resulting from an 
antibody response to exogenous growth factors have been reported on rare occasions in subjects treated with other recombinant growth factors. There is a theoretical possibility that an antibody directed against G-CSF may cross-react with endogenous G -CSF, resulting in immune -mediated neutropenia; however, 
this has not been reported in clinical studies or in post -marketing experience. Subjects who develop 
hypersensitivity to G -CSF may have allergic or hypersensitivity reactions to other E coli-derived proteins.  
 
Cutaneous Vasculitis:  Cutaneous vasculitis has been reported in subjects treated with G-CSF. In most 
cases‚ the severity of cutaneous vasculitis was moderate or severe. Most of the reports involved subjects with severe chronic neutropenia receiving long-term G -CSF therapy. Symptoms of vasculitis generally 
developed simultaneously with an increase in the ANC and abated when the ANC decreased. Many subjects were able to continue G-CSF at a reduced dose.  
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 46 of 74 
 
 Aortitis - inflammation of the aorta:   Aortitis  has been reported in patients who received G-CSF . 
Symptoms may include fever, abdominal pain, feeling tired, and back pain.   
The following AEs have been identified during post -approval monitoring of G-CSF: splenom egaly, 
splenic rupture, ARDS, alveolar hemorrhage and hemoptysis, sickle cell crisis, cutaneous vasculitis, aortitis, Sweet’s syndrome (acute febrile neutrophilic dermatosis), decreased bone density and 
osteo porosis in pediatric  severe chronic neutropenia subjects receiving chronic treatment with G-CSF.  
8.3 Risks and Discomforts of Phlebotomy
 
53TSubjects will undergo repeat blood sampling on several occasions during the initial phase of the study 
and during the treatment period. For research blood purposes, each venipuncture will be for 3 mL to 120 
mL of blood in adul ts. 53TPhlebotomy for blood tests may cause pain , lightheadedness/fainting, or lead to 
the formation of a small subcutaneous hematoma caused by blood leaking from a punctured blood vessel. The hematoma causes only minor discomfort ; it is not dangerous and requires no treatment other than 
reassurance to the subject. There is also a small risk of infection at the site of the needle puncture, which can be readily treated with antibiotic therapy. At the time of enrollment, each subject will be asked about 
their participation in other research studies to ensure that the amount of blood drawn does not exceed the limits allowed for ad ult subjects by the NIH Clinical Center (Medical Administrative Series Policy #:  
M95-9: Guidelines for Limits of Blood Drawn for Research Purposes in the Clinical Center. Available at:  
http://cc -internal.cc.nih.gov/policies/PDF/M95 -9.pdf  
8.4 Risks and Discomforts of Skin or Wart Biops ies 
Wart or skin biopsies may be requested for diagnosi s and research from subject s but will be optional. An 
expe rienced clinician  will perform the procedure. Unless the procedure is being performed in conjunction 
with a clinically indicated surgery, only local anesthetics will be used to prepare the biopsy site. The risks 
of wart biopsy include local pain, bleeding, infection, and the potential for scar and keloid formation. Antibiotics and oral analgesics will be used  to manage pain and infection. The differences in the immune 
response during plerixafor  and G -CSF treatment offers generalizable knowledge about the 
pathophysiology and treatment of this condition and knowledge of infecting types of HPV and the 
presence of other co -infecting viruses may have clinical implications for the subject  (i.e., risk of cancer 
development is increased with “high risk” HPV types).  
8.5 Risks and Discomforts of Bone Marrow Biopsy  
Subjects have the option of having bone marrow biopsy done for research purposes, which  could be 
performed as an outpatient procedure . Local anesthetics will  be used to prepare the biopsy site and IV 
conscious sedation may be offered to subjects for comfort; these agents may resul t in transient local 
discomfort initially and occasionally be associated with allergic reactions. General anesthesia will only be given if the participant is admitted for the procedure.  The primary risks of bone marrow biopsy include 
local pain, bleeding, and infection. Antibiotics and oral analgesics will be used to manage pain and 
infection.  
8.6 Risks of Stopping G -CSF  
Subjects receiving G-CSF at the time of randomization will have the agent stopped for two days prior to receiving the first dose of study drug.  This short washout period is to avoid the possibility of synergy 
between G-CSF and plerixafor.  The risk of infection during the two day washout period is unlikely to be significantly increased.  Moreover, the subject s will be closely monitored at the NIH-CC as outpatients 
during this per iod.   
8.7 Potential Benefit 
G-CSF is an  FDA-approved treatment for neutropenia and has been shown to reduce infection in 
congenital neutropenia .(
40T24 40T) ( 40TAppendix C 40T) Plerixafor  is a specific antagonist of CXCR4 and provides a 
novel molec ularly targeted potential therapy for WHIMS. Recent Phase I dose-escalation studies of 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 47 of 74 
 
 plerixafor  in a total of 9 subject s demonstrated  that the drug mobilizes not only neutrophils but also all 
other  leukocyte subsets that are decreased in the blood of WHIMS patients.( 40T3, 4 40T) Furthermore, low -dose 
therapy with plerixafor  alone for 6 months in 3 subjects resulted in a reduction of infections , no new warts 
and possible improvement of existing warts, and no safety concerns.(5) This collective experience 
appeared to be an improvement compared to pre and post study treatments of the same subjects with G -
CSF. 
8.7.1 Reduced Infections  
G-CSF has been shown to be effective in alleviating neutropenia and reducing infection in patients with 
chronic neutropenia ( 40T24 40T) and there is some limited anecdotal and retrospectively controlled evidence that 
plerixafor  may also have clinical benefits.  The aim of this study is to define which drug is superior in 
WHIMS patients. Th e crossover design ensures that all subject s are able to receive both treatments: 
subject s without prior treatment with either agent may  experi ence improved outcomes from either 
treatment, while subject s previously on G -CSF may obtain benefits with plerixafor . 
8.7.2 Improved Drug Tolerability  
In our clinical experience treating WHIMS patients with G-CSF and plerixafor, we have identified low 
dose rang es able to maintain the ANC within the target range for the present study of 500-1500 
cells/microliter, which is considered in the literature as ‘safe’ .  At these doses, we have observed no 
toxicity attributed to either plerixafor  or G-CSF and both appear to be well-tolerated.   
8.7.3 Control of Warts  
Limited evidence suggests that during chronic treatment with plerixafor in WHIMS patients , warts are 
improved in appearance and size and seem not to recur which is different from the patient’s prior 
experience on/off G -CSF therapy.  This may indicate a beneficial effect of plerixafor  treatment in HPV 
disease. (5)  This study is designed to further investigate and validate this preliminary result . 
8.7.4 Increased Leu kocyte Response 
Preliminary published evidence sugge sts that plerixafor  is capable of increasing all leukocytes measured 
that are diminished in the circulation of WHIM S patients (neutrophils, CD4+/CD8+ lymphocytes, B cells, 
and monocytes) in contrast to G -CSF, which increased mainly  neutrophils. (3-5)  It is currently unknown 
whether the increased circulating leukocytes convey the expected benefits in terms of reducing infection 
or improving the immune system function and this study is designed to further investigate and validate 
this. 
9 RESEARCH USE OF STORED HUMAN SAMPLES, SPECIMENS OR DATA  
9.1 Intended Use  
Sample collection, handling, storage, and shipment will follow NIH-CC policies and procedures. We will 
make a summary of radiology and laboratory resul ts available to subjects and their local  physicians.  
Sample s and data collected under this protocol may be used to study the causes of primary 
immunodeficiency, the consequences thereof, and its treatment. Genetic testing to determine the cause of 
the underlying disorder will be performed utilizing another appropr iate protocol and will not be 
performed as part of this protocol .  
9.2 Storage and Tracking  
Access to stored samples will be limited using either a locked room or a locked freezer. Samples and data will be stored using codes assigned by the investigators. Data will be kept in password -protected 
computers. Only investigators will have access to the samples and data. Samples and data acquired will be tracked using software designed for this purpose.  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 48 of 74 
 
 9.3 Sharing of Samples and Data  
Other investigators at the NIH or ou tside  may wish to study these samples and/or data. In that case, IRB 
approval must be sought prior to any sharing of samples and/or data. Any clinical information shared about the sample wo uld similarly require prior IRB approval . 
9.4 Reporting Loss or Unanticipated Destruction of Samples  
Any loss or unanticipated destruction of samples or data (for example, due to freezer malfunction) that is 
a Serious Protocol Deviation or compromises the scientific integrity of the data collected for the study, 
will be repor ted to the National Institute of Allergy and Infectious Diseases (NIAID) IRB. 
9.5 Disposition of Samples  
9.5.1 Request by Study Participant  
Subjects may decide at any point not to have their samples stored. The P I will destroy or assure the 
destruction of all known remaining samples and report what was done to both the subject and to the IRB. This decision will not affect the subject’s participation in other protocols at NIH.  
9.5.2 At Completion of Study  
At the completio n of the protocol (termination), samples will either be destroyed, or after IRB approval, 
transferred to another existing protocol . 
10 REMUNERATION PLAN FO R SUBJECTS  
Study subjects and their families will not receive any per visit reimbursement  for the clinical trial. 
However for optional procedures performed for research purposes only, $120.00 will be paid for each wart and/or skin biopsy, and $200 paid for each bone marrow biopsy.  
11 ASSESSMENT OF SAFETY  
11.1 Documenting, Recording, and Reporting Adve rse Events  
At each contact with the subject, information regarding AEs will be elicited by appropriate questioning 
and examinations and they will be:  
• Immediately documented in the subject’s medical record/source document. 
• Recorded in Clinical Research In formation Mana gement System , and  
• Reporte d as outlined below (e.g., IND s ponsor, IRB, FDA). 
11.2 Definitions  
Adverse Event (AE)  
An AE is any untoward or unfavorable medical occurrence in a human subject, including any abnormal 
sign (e.g., abnormal physical exam or laboratory finding) , symptom , or disease, temporally associated 
with the subject’s participating in the research, whether or not considered related to the research.  
 Adverse Reaction (AR) or Adverse Drug Reaction (ADR)   
An AE  that is caused by an investigational agent (drug or biologic).  
 Suspected Adverse Reaction (SAR)  
An AE  for which there is a reasonable possibility that the investigational agent caused the AE . 
‘Reasonable possibility’ means that there is evidence to suggest a causal relationship between the drug and the AE. A SAR  implies a lesser degree of certainty about the causality than an AR,  which implies a 
high degree of certainty.  
 Serious Adverse Event (SAE) 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 49 of 74 
 
 A serious AE  (SAE ) is an AE  or any untoward medical occurrence  that at any time results in 1 or more of 
the following outcomes:  
• Death  
• Life threatening event (immediate threat to life)  event   
• An inpatient hospitalization or prolongation of an existing hospitalization,  
• A persistent or significant incapacity or substanti al disruption of the ability to conduct normal life 
functions,  
• A con genital anomaly or birth defect , 
• A medically important event *  
 *Medical and scientific judgment sho uld be exercised in deciding whether other situations should be 
considered serious, such as important medical events that may not be immediately life threatening or resul t in death or hospitalization , but they may jeopardize the subject or may require intervention to 
prevent 1 of the other outcomes listed above.  
 
Unexpected Adverse Event   
An AE is unexpected if it is not listed in the Investigator’s Brochure or Package Insert (for marketed 
products) or is not listed at the specificity or severity that has been observed.  It is the responsibility of the IND Sponsor to make this determination.  
 
Serious and Unexpected Suspected  Adverse Reaction (SUSAR)  
A SUSAR is a Suspected Adverse Reaction that is both Serious and Unexpected.   
 
Unanticipated Problem  (UP)   
An UP is any event, incident, experience, or outcome that is  
1. Unexpected in terms of nature, severity, or frequency in relation to: 
• The research risks that are described in the IRB -approved research protocol and informed consent 
document, investigator’s b rochure , or other study documents; and 
• The characteristics of the subject pop ulation being studied; and  
2. Possibly, probably, or definitely related to participation in the research; and 
3. Places subjects or others at a greater risk of harm (including physical, psychological, economic, or 
social harm) than was p reviously known or recognized. Per the IND sponsor, an AE with a serious 
outcome will be considered increased risk.  
 Unanticipated Problem That I s Not an Adverse Event (UPnonAE)  
Unanticipated problem that is not an Adverse Event (UPnonAE): An unanticipated problem that does not fit the definition of an adverse event, but which may, in the opinion of the investigator, involve risk to the 
subject, affect others in the research study, or significantly impact the integrity of research data.  Such 
events would be considered a non-serious UP. For example, we will report occurrences of breaches of confidentiality, accidental destruction of study records, or unaccounted -for study drug.  
 Protocol Deviation  
Any change, divergence, or departure from the IRB approved study procedures in a research protocol. Protocol deviations are designated a s serious or non -serious and further characterized as  
 1. Those that occur because a member of the research team deviates from the protocol. 
2. Those that are identified before they occur, but cannot be prevented.  
3. Those that are discovered after they occur  
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 50 of 74 
 
 Serious Protocol Deviation: A deviation that meets the definition of a Serious Adverse Event or 
compromises the safety, welfare or rights of subjects or others.  
 
Non –compliance :  The failure to comply with applicable NIH HRPP policies, IRB requirem ents, or 
regulatory requirements for the protection of human subjects. Non-compliance is further characterized as  
1. Serious: Non -compliance that  
a. Increases risks, or causes harm, to participants 
b. Decreases potential benefits to participants 
c. Compromises the integrity of the NIH-HRPP 
d. Invalidates the study data 
2. Continuing: Non-compliance that is recurring  
3. Minor: Non-compliance that, is neither serious nor continuing.  
11.3 Investigator Assessment of Adverse Events 
If a diagnosis is clinically evident (or subsequently determined), the diagnosis rather than the individual 
signs and symptoms or lab abnormalities will be recorded as the AE.  All AEs occurring after enrollment  
through the final study visit will be documented and recorded , and those not related to disease progression 
will be reported as described below in Section 11.4 and Section 11.5 .   
 A laboratory abnormality should be reported as an AE if it requires an intervention. Interventions include, but are not limited to, discontinuation of treatment, dose reduction/delay, additional assessments, or concomitant treatment. In addition, any medically important laboratory abnormality may be reported as an AE at the discretion of the investigator. This could include a laboratory result for which there is no intervention but the abnormal value suggests disease or organ toxicity.  
 The i nvestigator will ev aluate all AEs with respect to the seriou sness (criteria listed above), severity 
(intensity or grade), and c ausality (relationship to the study agent and relationship to research) according 
to the following guidelines.  
11.3.1  Severity  
The investigator will grade the severity of each AE according t o the “Common Terminology Criteria for 
Adverse Events (CTCAE)” (v 4.0):  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  
 
Severity grading for clinical events not found in the toxicity table will be graded according to the  
following grading scale:  
1. Grade 1 (Mild):  Events causing no or minimal interference with usual social and functional 
activities . 
2. Grade 2 (Moderate ): Events causing greater than minimal interference with usual social and 
functional activities . 
3. Grade 3 (Severe) : Events causing inability to perform usual social and functional activities . 
4. Grade 4 (Potentially Life -Threatening) : P 
PEvents causing inability to perfor m basic self -care 
functions OR medical or operative intervention is indicated to prevent permanent imp airment, 
persistent disability, or death .  Note:  A  severity assessment of “potentially life -threatening” event 
is not necessarily the same as a life -threatening event, when used as an "SAE" criterion. The latter 
means that the event is an immediate threat to life as opposed to a potential threat to life.  
5. Grade 5 (Death) .  
11.3.2  Causality    
Causality (likelihood that the event is/is not related to th e study agent)  will be assessed considering the 
factors listed under the following categories:  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 51 of 74 
 
 Definitely Related   
• Reasonable temporal relationship . 
• Follows a known response pattern . 
• Clear evidence to suggest a causal relationship . 
• There is no alternative etiology . 
 
Probably Related 
• Reasonable temporal relationship . 
• Follows a suspected response pattern (based on similar agents). 
• No evidence of a more likely alternative etiology . 
 Possibly Related  
• Reasonable temporal relationship . 
• Little evidence for a more likely alternative etiology . 
 Unlikely Related  
• Does not have a reasonable temporal relationship .  
OR 
• Good evidence for a more likely alternative etiology . 
 
Not Related  
• Does n ot have a temporal relationship.          
OR 
• Definitely due to an alternative etiology . 
 
Note: Other factors (e.g., dechallenge, rechallenge) sho uld also be considered for each causality category , 
when appropriate. Causality assessment is based on available information at the time of the assessment of  
the AE. The investigator may revise the causality assessment as additional information becomes 
available. 
11.4 Investigator Reporting Responsibilities to the Sponsor  
11.4.1  Adverse Events 
Line listings, frequency tables, and other summary AE data will be submitted to the IND sponsor when 
needed for periodic safety reviews, review of IND annual reports, review of IND safety reports, and 
preparation of final study reports.  
11.4.2  Serious Adverse Events  
All SAEs (regardless of relationship and whether or not they are also UPs)  must be reported on the Safety 
Expedited Report Form (SERF) and sent to  the Sponsor Clinical Safety Office (CSO) by fax or e- mail 
attachment. Deaths and immediately life threatening SAEs must be reported to the CSO within 1 business day after the site becomes aware of the event. All other SAEs must be reported within 3 business days of 
site awareness. 
 
SPONSOR CLINICAL SAFETY OFFICE CONTACT INFORMATION:  
OCRPRO Clinical Safety Office  
5705 Industry Lane  
Frederick, MD 21704  
Phone : 301-846-5301  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 52 of 74 
 
 Fax: 301-846-6224  
E-mail: rchspsafety@mail.nih.gov   
11.4.3  Unanticipated Problems  
Unanticipat ed Problems that are also adverse events must be reported to the CSO and sent by fax or e-
mail attachment no later than 7 calendar days of site awareness of the event. UPs that are not AEs are not reported to the Sponsor CSO.  
Report all UPs that are also adverse events to the CSO on the NIH Problem Report Form.  
11.4.4  Protocol -Specified Events  
There are no protocol -specified events.  
11.4.5  Pregnancy  
Pregnancy itself is not an AE. However, complications from pregnancy are AEs and may be SAEs. Pertinent obstetrical information for all pregnancies will be reported to the CSO via fax or e- mail within 3 
business days from the site’s awareness of the pregnancy.   
 
Pregnancy outcome data (e.g., delivery outcome, spontaneous, or elective termination of the pregnancy) will be reported to the CSO within 5 business days of the site’s awareness of the outcom e on a protocol -
specified form. In the event of pregnancy, the subject will be followed to term for safety monitoring.  In 
the event of pregnancy : 
• Treatment for  the subject  will be un -blinded;  
• If subject  is being treated with plerixafor , the study drug will be discontinued; 
• If subject  is being treated with G-CSF, the study comparator drug may be withheld for  the 1
Pst
P 
trimester;  
• Subject will be advised to notify their obstetrician;  
• Pregnancy will be reported to the Data Safety Monitoring Board (DSMB).  
11.5 Investigator Reporting Responsibilities to the NIAI D IRB  
11.5.1  Expedited Reporting  
Serious and non-serious Unanticipated Problems, deaths, serious deviations, and serious or continuing non-compliance will be reported within 7 calendar days of investigator awareness. Serious Adverse Events that are possibly, probably, or definitely related to the research will be reported to the NIAID IRB within 7 calendar days of investigator’s awareness, regardless of expectedness.  
11.5.2  Waiver of Reporting Anticipated Protocol Deviations, Expected UPnonAEs and Deaths   
Anticipated deviations in the conduct of the protocol will not be reported to the IRB unless they occur at a rate greater than anticipated by the study team. Expected adverse events will not be reported to the IRB unless they occur at a rate greater than that known to occur in WHIMS . If the rate of these events exceeds 
the rate expected by the study team, the events will be classified and report ed as though they are 
unanticipated problems. Deaths related to the natural history of WHIMS  will be reported at the time of 
continuing review.  
11.5.3  Annual Reports   
The following items will be reported to the NIAID IRB in summary at the time of continuing revi ew: 
• Serious and non-serious unanticipated problems  
• Expected SAEs that are possibly, probably, or def initely related to the research; 
• SAEs that are not related to the research;   
• All adverse events, except expected AEs and deaths granted a waiver of reporting.  
• Serious and Non-Serious Protocol deviations  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 53 of 74 
 
 • Serious, continuing, and minor non-compliance 
• Any trends or events that in the opinion of the investigator should be reported.  
11.6 Follow -up of Adverse Events and Serious Adverse Events  
AEs that occur following enrollment of the subject (by signing the informed consent) are followed until 
the final outcome is known or until the end of the study. AEs that have not resolved by the end of  the 
study will be recorded as “ongoing” , and will be  followed until the final outcome is known. If it is not 
possible to obtain a final outcome for an SAE , the investigator will record the reason a final outcome 
could not be obtained. SAEs that occur after the end of the study that are reported to and are assessed by 
the investigator to be possibly, probably, or definitely related must be reported to the CSO, as described 
above.  
11.7 Investigator Initiated Trial (IIT) Sponsor  Obligations a nd Reporting Responsibilities  
Serious and unexpected suspected adverse reactions as defined in FDA 21 Code of Federal Regulations 
(CFR) 312.32 and determined by the IND sponsor will be reported to the FDA as IND safety reports. The 
IND sponsor will also su bmit an IND Annual Report of the progress of the investigation to the FDA, as 
defined in 21 CFR 312.33.  AEs that are also UPs will be summarized by the IND sponsor and distr ibuted 
to investigators . 
 For this Investigator Initiated Trial (II T): 
• The IIT  sponsor (OCRPRO) warrants that the study will be performed in compliance with all 
applicable local and international laws and regulations, including without limitation ICH E6 
guidelines for Good Clinical Practices.  
• The IIT sponsor shall be responsible for the respect of all obligations required by applicable local 
and international laws and regulations.  
• The sponsor shall be responsible for ensuring submission of required expedited and periodic reports to the FDA and the NIAID IRB.  The IIT sponsor is responsi ble for providing any “Dear 
Investigator Letter” (DIL) for new safety finding received from Sanofi group entity to the investigators and Ethics Committee .  
• The sponsor must report the following information in English to the Sanofi group entity Pharmacovigi lance contact:  
1. Routine transmission of: All Serious Adverse Events (SAEs). These events must be transmitted within 1 working day of the sponsor ’s awareness or identification of the event.  
     Results of any relevant complementary exams performed to obtain the final diagnosis of any 
SAE (e.g., hospital discharge summary, autopsy, consultation) will be made available to Sanofi group entity upon request.  
2. Other events or periodic reports (e.g. Development Safety Update Report (DSUR)), submitted to the  FDA must be transmitted at the time of submission.  
3. Other significant safety issues or findings in a study pertaining to safety of product must be 
transmitted within 3 working day s. 
4. The study report of any IIT must contain a section describing safety  review and conclusion.  
5. The reference safety information to be used by the IIT sponsor for evaluation of expectedness 
of adverse events shall be the current approved product label available in the country.  
  
SANOFI GROUP ENTITY PHARMACOVIGILANCE CONTACT  
 
Fax/email of SAE Reports to  Sanofi: 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 54 of 74 
 
  IST/ISS Investigators will notify Sanofi  via fax or email, attention Sanofi  Pharmacovigilance (PV):  
  
Fax:  908 -203-7783 (US)    
E-mail :USPVmailbox@sanofi.com  
11.8 Halting  Criteria for the Protocol  
Halting the study requires immediate discontinuation of the study agent administ ered to subjects and 
suspension of enrollment in this study until a decision is made whether or not to contin ue the study agent 
administration.  
 
The halting criteria  include:  
1. Two or more subjects experience the same or similar SAEs that are unexpected and are possibly, 
probably, or definitely related to the study agent , or 
2. Any safety issue that the site investigators determine sho uld halt the study .  
 The IRB,  IND sponsor, or the FDA may halt the study at any time following review of any safety 
concerns. The DSMB may recommend a study halt.  
11.8.1  Reporting of Study Halting  
If a halting requirement is met, a description of the event(s) or safety issue must be reported by the PI 
within 1  busin ess day to the sponsor CSO by fax or e -mail. The PI must inform the IRB that a halting 
requirement has been met.  
11.8.2  Resumption of a Halted Study  
The IND sponsor, in collaboration with the PI and the DSMB , will determine if it is saf e to resume the 
study. The IND s ponsor will notify the PI of this decision. The conditions for resumption of the study will 
be defined in this notification. The PI  will notify the IRB  of the decision to resume the study.  
11.9 Pausing Criteria for a Subject  
The decision to suspend admini stration of a study agent for a single subject requires discontinuation of 
study agents administrated to the study subject until a decision is made whether or not to continue the 
administration of the study agent.   
 
The pausing criteria for a single subje ct in this study include:  
1. A subject experiences an SAE or a  grade 3 or greater AE that is unexpected  (as determined by the IND 
Sponsor)  and is possibly, probably, or definitely related to the study agent; or 
2. Development of any exclusion criteria may be cause for discontinuation; or 
3. Any safety issue that the investigator determines should pause administration of the study agent to a single subject . The IND sponsor, in collaboration with the PI, may also pause for an individual subject 
if a safety concern is identified during routine aggregate data analysis. 
11.9.1  Reporting of Pausing for a Subject  
If a pausing requirement is met, a description of the AEs or safety issue must be reported by the site investigator via fax or email within 1 business day to the sponsor CSO, PI, the IRB and the DSMB.  
11.9.2  Resumption of a Paused Study  
The IND sponsor in collaboration with the PI and DSMB will determine if it is safe to resume 
administration of the study agents to the subject/group. The IND sponsor will notify the si te investigators 
of this decision. The site investigators will notify their local IRB(s) of the decision to resume administration of the study agents prior to resumption.   
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 55 of 74 
 
 11.10 Withdrawal Criteria for an Individual Subject  
An individual subject will be withdra wn from the study for any of the following:  
1. A subject’s decision (investigator shoul d attempt to determine the rea son for the subject’s 
decision).  
2. Any clinical AE, laboratory abnormality , or other medical condition or situation such that 
continued participation in the study woul d not be in the best interest of the subject.   Subjects will 
be followed for the duration of the study for indicated safety assessments.  
3. Non-compliance with study procedures to the extent that it is potentially harmf ul to the subject or 
to the integrity of the study data.  
4. A change in the subject’s baseline condition after enrollment so that the subject no longer meets the inclusion/exclusion criteria.   
11.11 Additional Enrollment for Withdrawn Subjects  
Subjects who are not evaluable as described in the Statistics ( Section 14) may be replaced with other 
eligible subjects . 
12 SAFETY OVERSIGHT AND MONITORING PLAN  
12.1 Safety Review and Communication Plan 
A Safety Review and Communication Plan (SRCP) has been developed for the protocol. The SRCP is an 
internal communications document between the PI and the IND sponsor CSO, which delineates the safety 
oversight responsibilities of the PI, the CSO, and other stakeholders. The SRCP also includes the overall 
plan for conducting periodic safety surveillance assessments. 
12.2 Sponsor Medical Monitor  
A sponsor medical monitor  representing the IND sponso r (OCRPRO ), has been appointed for the safety 
oversight in this clinical study. The sponsor medical monitor will be responsible for performing safety 
assessments as outlined in a Safety Review and Communications Plan.  
12.3 Data and Safety Monitoring Board   
The NIAID intramural DSMB will review the IRB-approved protocol, informed consent documents, data 
and safety monitoring plan and any stopping guidelines of the study prior to initiation and twice a year. 
The board may convene additional reviews as necessary.  The board will review the study data to evaluate the safety, efficacy, study conduct and progress, and scientific validity and integrity of the trial. All SAEs, 
UPs, and IND safety reports will be reported by the PI to the DSMB at the same time they are submitted 
to the IRB or IND sponsor. As part of this responsibility, the DSMB members must be satisfied that the 
timeliness, completeness, and accuracy of the data submitted to them for review are sufficient for evaluation of the safety and welfare of the study subjects. The DSMB may also convene as needed, if stopping criteria are met, or other safety issues arise that the PI and/or NIAID clinical director or designee 
would like the DSMB to address.  The PI will notify the DSMB of any cases of intentional  or 
unintentional unblinding as soon as possible. The PI will notify the board at the time pausing or halting 
criteria are met and obtain a recommendation concerning continuation, modification, or termination of the study. The PI  will submit the written DSMB recommendations and summary reports to the NIAID IRB.  
12.4 Procedures for Emergency Unblinding  
In the event of a pregnancy occurring during treatment or Grade 4 or 5  toxicity in a participant their drug 
treatment will be unblinded and the  subject  and their local physician will be told of their status.  
Whenever possible the PI and investigators will not be made aware of their treatment status.  If this is unavoidable, the IRB, DSMB, and CSO will be notified. 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 56 of 74 
 
 13 CLINICAL MONITORING STRUCTURE  
13.1 Site Monitoring Plan  
As per International Conference on Harmonization (ICH) Good Clinical Practice (GCP) 5.18, clinical protocols are required to be adequately monitored by the study sponsor. This study monitoring will be conducted according to the NIAID Intramural Clinical Monitoring Guidelines. Monitors under contract to the NIAID/ OCRPRO will visit the clinical research site to monitor all aspects of the study in accordance 
with appropriate reg ulations and the approved protocol. The objectives of a monitoring visit will be: 1) to 
verify the existence of signed informed consent documents for each monitored subject; 2) to verify the prompt and accurate recording of all monitored data points and prompt reporting of all SAEs; 3) to compare abstracted information with individual subjects’ records and source documents (subjects’ charts, laboratory analyses and test resul ts, physicians’ progress notes, nurses’ notes, and any other relevant 
original subject information); and 4) to ensure the investigators compliance with the protocol,  and 
completeness and accuracy of the study records. The monitors also will inspect the clinical site reg ulatory 
files to ensure that reg ulatory requirements (Office for Human Research Protections [OHRP]) and 
applicable guidelines (ICH -GCP) are being follo wed. During the monitoring visits, the investigator 
(and/or designee) and other study personnel will be available to discuss the study progress and monitoring visit. 
  
The investigator (and/or designee) will make study documents (e.g., consent forms, and pertinent hospital or clinical records) readily available for inspection by the local IRB, site monitors, and NIAID staff for confirmation of the study data. A specific protocol -monitoring plan will be discussed with the PI and 
study staff prior to enrollment. The plan will outline the frequency of monitoring visits based on factors such as study enrollment, data collection status, and reg ulatory obligations.  
 A monitoring visit will occur after the first five participants have been treated for 6 months in o rder to 
ensure completeness of reports sent by outside labs and to verify the presence of  Memory Aid  forms. 
14  STATISTICAL CONSIDER ATIONS  
14.1 Study Hypotheses  
The primary hypothesis is that the Total Infection Severity Score (TISS) will be significantly reduced  
while on plerixafor compared to GCSF. The TISS score is the sum of the Infection Severity Scores (
40TAppendix D 40T) for all infections during each period (1 year of treatment). Secondary endpoints include 
infection related parameters, wart response, immunological parameters, and measures of chronic 
infections, side effects, quality of life, and treatment preference.  
14.2 Sample Size Justification 
The primary endpoint is the change  in the total infection severity score dur ing period 1 minus the total 
infection severity score during period 2. Retrospective data on 11 subjects treated with  G-CSF for one 
year provide d a mean TISS score of 21  with a  standard deviation of 10.  We conservatively assume that 
there will be a reduct ion of 50% between the TISS score during the plerixafor period and the TISS score 
during the G -CSF period. Table 1 provides some power calculations based on a two group t -test using an 
alpha = 0.05 two-sided test and setting power at 90%.  The groups are d efined by their randomization 
sequence Gp (meaning G- CSF first then plerixafor)  or pG (for plerixafor treatment  first, followed by G -
GSF).    
Table 1 :  Sample size required to achieve 90% power under different assumptions for the mean 
response on G -CSF and plerixafor.  Power formula based on a two -sided two sample t -test with 
alpha=0.05 using the period 1 minus period 2 change in TISS scores as the primary outcome. A 
standard deviation of 10 for the difference is assumed.  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 57 of 74 
 
 Mean T ISS 
while on G -CSF  Mean  
TISS 
while on 
plerixafor  Percent  
Reduction in 
TISS  Mean Change 
for 
Gp group Mean 
Change 
for pG 
group  Mean 
Difference 
in changes 
between 
groups  Total 
Sampl
e Size  
21 10 52.4%  11 -11 22 12 
21 11 47.6%  10 -10 20 14 
21 12 42.9%  9 -9 18 16 
21 13 38.1%  8 -8 16 20 
21 14 33.3%  7 -7 14 24 
 
From Table 1, we see that with 16 -20 subject s we can detect 38% -43% reductions in TISS while on 
plerixafor.   Such reductions would be clinically meaningful and we will thus aim to enroll 20 subjects.  
While the Wilcoxon two sample rank sum test will be used in the analysis to provide some robustness 
against aberrant TISS scores, the power based on a t-test is a good approximation to the power for a 
Wilcoxon test. We use the two sample Wilcoxon test instead of the one sample paired difference Wilcoxon test to provide robustness to the possibility of secular trends in the TISS score over the two 
periods.   
14.3 Study Population  
Our study population will be genetically proven WHIM patients (known compatible heterozygous CXCR4 mutation) age 10- 75 who have a history of recurrent infections and are neutropenic (ANC<1500 
at baseline).  These individuals would be likely to benefit from either the study drug or the comparator agent.  Subjects will be recruited for participation among those being followed at NIH ( 24 as of May 
2014), followed elsewhere in the US or other countries, newly diagnosed by dermatologists, immunologists, gynecologists, urologists, or primary care physicians or self -referred.   
As with U S subjects , subjects recruited from other countries will receive their routine care and obtain 
blood counts from their local providers and visit the NIH -CC per study schedule. 
14.4 Description of Analysis  
14.4.1  Efficacy Analysis – Infection Severity Score (ISS)  
Data from a subject ’s study Memory Aid  such as visits to a subject ’s local medical provider, anti -
infective prescriptions, fevers (oral temperature >38.3
Po
PC), h ospitalization, and diagnoses of infection 
from the subject ’s medical provider, are collected, reviewed and scored at the study center  by the P I 
according to specific pre-defined weighting rules ( 40TAppendix D 40T) designated the ISS. 
14.4.1.1   Infection -related Events  
An Infection -related Event is defined by any of the following:  
1) Diagnosis of Infection by a Clinician : Subject s are encouraged to visit their local medical 
provider if they experience symptoms of a new or worsening infection such as fevers, chills, aches, pain, worsened cough, swelling, redness, etc. Subjects record visits to their local medical 
provider in their Memory Aid  and provide documentation of the diagnosis and treatment to the 
NIH-CC. If a provider clinically diagnoses an infection (i.e. otitis, sinusitis, dental infection, bronchitis, pneumonia, ab scess), th is is recorded and counted as an Infection-related Event.  
2) Presumed Diagnosis of Infection by a Clinician: The precise cause of an infection cannot always 
be determined. A differential diagnosis of possible infections and/or biomarker indications  of an 
infection will be counted as an infection.  
3) Resolution of Infection Symptoms after Treatment with Antibiotics : Subjects with chronic or 
recurrent infections may have a standing prescription for antibiotics without need to visit their 
local medical providers prior to initiating treatment. Because subjects record their symptoms of 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 58 of 74 
 
 infection and any antibiotic taken for treatment in their Memory Aid  ( 40TAppendix F 40T), resolution of 
likely symptoms of infection (for example fever, pain, or worsened cough) coincident with commencing an  antibiotic regimen  will be counted as an Infection -related Event  even if not 
diagnosed clinically.  
14.4.1.2  Severity of Fever for an Infection -related Event  
The highest temperature recorded during an episode of infection is scored as described in 
Appendix D . 
Fevers that are of indeterminate origin (i.e. not clearly associated with an Infection) are counted as a fever, but are not included in the ISS.  
14.4.1.3  Level of Antibiotic Treatment for an Infection-rela ted Event  
The highest level of prescribed antibiotic treatment (topical, oral, or parenteral) for an Infection is scored 
and described in the Infection Severity Score in 
40TAppendix D 40T.  
14.4.1.4  Extent of Hospitalization for an Infection-r elated Event 
The highest level of care i s scored as described in the Infection Severity Score in Appendix D .  
14.4.2  Method of Analysis  
For the primary analysis of our data we will use a two-sample  Wilcoxon test under a ranking scheme 
where we form a score for each person  
  
S = (TISS during period 1 – TISS during period 2),  
 
where TISS is the Total Infection Severity Score , which is the sum of all ISSs during a period. For 
example, if a subject  had 3 infections on plerixafor with ISSs of 4, 1, 3 and 2 infections on GCSF with 
ISSs of 5,1, the score would be (4+1+3) – (5+1) = 8 -6=2.    
 
It is possible that not all subject s will have complete follow-up for both periods.  We next describe how to 
handle such subjects. Drug failures are subjects who must discontinue their assigned drug because 1) drug 
is intolerable and the subject  refuses to take the study drug , 2) the ANC is reliably less than 500 cells/µL 
or 3) an adverse event preclud es further study drug administration.  Drug fa ilures in tr eatment period 1 
cross over to the opposite arm ; drug failures in treatment period 2 re ceive best available therapy.  A drug 
failure should get the worst rank. Let S* be the largest of the absolute value of the scores for all subjects 
with complete data.  To operationalize giving the worst rank, we will give drug failure s during the first 
period a score of S*+1. If a drug failure occurs during the second period, they receive a score of -(S*+1).  
Subjects who are drug failures in each period receive a score of 0.    
 Apart from drug failures, some subject s may drop out of the study for reasons different than the above 
three. F or subject s who drop out in period 2 after at least 3 months of follow-up  an adjus ted score will be 
formed. 
S = TISS in period 1 -  (TISS in period 2)/f  
 
where f is the fraction of intended follow -up attained in period 2 (note that f>=3/12). Based on these 
scores, we will calculate a permutation p -value using the  two-sample Wilcoxon rank test. Subjects who 
drop out in period 1 or before 3 months of period 2 will be excluded from the primary analysis.  
 If missing data and drug failures are substantial, different sensitivity analyses will be conducted. These could include discarding all s uch subject s or developing a model to help allow imputation of missing data, 
or performing a model based analysis.  
 All tests will be two-sided with a type I error rate of 0.05.  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 59 of 74 
 
 14.4.3  Interim Analysis 
After 10 subject s have data for the primary analysis, an interim analysis will be performed. If the two -
sample Wilcoxon test of TISS scores achieves a one-sided permutation p-value of 0.05 or less indicating 
better TISS scores on G-CSF versus plerixafor, serious consideration should be given to stopping the 
study f or futility.  
 A subject  has data for the primary analysis if  
1) They have completed 1 year of plerixafor treatment and 1 year of G -CSF treatment  
2) Are a drug failure on either plerixafor or G -CSF (or both) 
3) They drop out in period 2 after 3 months of follow -up. 
 No interim analysis for efficacy is planned; it is difficult for a rank -based procedure to achieve a small p -
value after 10 subject s, and we anticipate the study will be entirely or nearly entirely enrolled by the time 
10 subject s have complete data for the primary endpoint.    
14.4.4  Futility Monitoring  
The study will be monitored for operational futility.  If fewer than 10 subjects have been enrolled  
after 2 years (counting time from the first enrollment), or if it is clear earlier that fewer than 10 subject s 
will be enrolled after 2 years, the study will be closed to further recruitment, and subjects already enrolled may choose to continue on the study or revert to best available medical therapy. If after 3 years the 
recruitment has plateaued at some level less than 20, the DSMB should consider closing the study to further recruitment while continuing the study of the enrolled subjects until all have data for the primary 
analysis.     
14.4.5  Safety Analy sis 
The following tables of AEs will be completed  after unblinding the study : 
• A listing of all SAEs including the treatment arm to which the subject was assigned.  
• Frequency tables of AEs by treatment arm, severity, and reported relationship to treatment.  
14.4.6  Secondary Analysis  
14.4.6.1  Secondary endpoints  
 Secondary endpoints (incidence of fevers and number of febrile days, incidence of hospitalization and 
number of hospital days, incidence of antibiotic treatment and number of antibiotic days, number of 
infections an d number of days with infections, number of new visible warts, and the change in severity 
for existing warts) will follow the same type of analysis as described above with the TISS being replaced by number of fevers, number of febrile days, etc. All tests will be two -sided with a type I error rate of 
0.05.  
14.4.6.2  Incidence and Duration of Infection -related Event  
An infection -related Event will be counted as an incidence of infection . The duration of infection is the 
number of days the symptoms of infection are pr esent.  
14.4.6.3  Incidence and Duration of Fever  
Febrile d ays are defined as day s in which the subject’s oral temperature  ≥ 38.3°C, at any point during the 
day (or 24 hour period). Contiguous days of f ever will be counted as an incidence of fever . For 
subsequent fevers to be considered a new/additional incidence of fever, an interval of at least 48 hours 
without fever related symptoms such as elevated temperature, chills, aches, and fatigue must separate each event of a fever.   
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 60 of 74 
 
 14.4.6.4  Incidence and Duration of Antibiotic  Treatment  
A prescribed treatment with a new antibiotic (oral, IV, or topical) is counted as an incidence of antibiotic 
treatment.  The duration of antibiotic treatment is the number of days a subject is under treatment with an 
antibiotic other than a prop hylactic antibiotic; missing an occasional dose does not invalidate the count 
for that day. For example if a subject  is asked to take a 10 day course of antibiotics for otitis this will 
count as one episode of otitis and 10 days of antibiotic therapy regar dless of whether the subject  actually 
takes all 10 days or misses a day.  Additional antibiotic treatments during or after the initial treatment are counted as additional incidences of antibiotic treatment. 
14.4.6.5  Incidence and Duration of Hospitalization 
An incidence of hospitalization is an admission to a hospital for treatment of an infection  or presumed 
infection . Hospital days are defined as any day that a subject  is in a hospital for treatment due to a 
diagnosis (or presumed diagnosis) of infection. The duration of an infection related event is the number of 
days the symptoms of infection persists.  
14.4.6.6  Severity of Chronic Infections 
Subjects with chronic and/or frequently recurring infections record the severity of their symptoms in their 
Memory Aid . At the Initial Evaluation period prior to randomization and treatment, a baseline of their 
symptoms is documented and incorporated into their Memory Aid . During treatment, any significant 
change in baseline such as worsening infection that affects their function or require symptomatic 
treatment (e.g. , over the counter medication) are recorded, as well as any significantly improved 
symptoms that improves their function or reduces their need for symptomatic treatment (e.g. , over the 
counter medication) are computed as used as a measure of their severity of infection.  
14.4.6.7  Use of Prophylactic Antibiotics  
At the Initial Evaluation period prior to randomization and treatment, a subject’s use of prophylactic 
antibiotics is documented and incorporated into their Memo ry Aid . Subjects record their compliance with 
these prophylactics in their Memory Aid . Changes in prescription or to a subject ’s use of the prophylactic 
are recorded . Although this information is not a direct measure of a subject ’s severity of infection, i t is 
collected to provide background information that may explain  confounding or extrinsic factors that may 
affect a subject’s rate and severity of infection.  Subjects who are prescribed prophylactic antibiotics will 
be encouraged to continue them throughout the study so as to minimize any confounding.  
14.4.6.8  Control of Warts  
Existing warts will be documented at baseline visits prior to treatment with either the study drug or the 
comparator agent via clinical photographs,  if the subject  consents. Every 4 months during the treatment 
period clinical photography will be repeated in areas with new or existing warts.  Our main endpoint will 
be the number of new visible wart s occurring during each 52-week  treatment period. We will also analyze 
the size changes of existing untreated warts and the regrowth of treated/removed warts as secondary endpoints. A two-sample Wilcoxon paired difference test will be used for analysis.  
14.4.6.9  Change of Leukocyte Blood Counts  
Leukocyte numbers  available from the CBC (ANC, etc.) will be averaged throughout each 1-year 
treatment period with either the Study Drug or Comparator Drug and statistical comparison will be performed as part of the secondary endpoints.  Lymphocyte flow cytometry results (CD19+, CD4+, CD8+, etc.) will be averaged from the 4, 8, and 12 month visits to the NIH-CC for each agent.  In 
addition both of these averages will be compared to the subject baseline defined as the average of any 
measurements of G-CSF and plerixafor  within 6 months of starting the study at NIH-CC. A two-sample 
Wilcoxon paired difference test will be used for analysis. Changes in leukocyte numbers will also be analyzed by length of time on the Study Drug or Comparator Drug.
   
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 61 of 74 
 
 14.4.6.10    Quality of Life and Subject Preference Assessment 
The subject s will complete a  validated  Quality of Life (QOL) questionnaire  (SF-36 version 2) during the 
4, 8, and 12 month visits in the Treatment period at the NIH-CC , and the responses will be averaged  and 
compared. Changes in QOL  scores will also be analyzed by length of time on the Study Drug or 
Comparator Drug.  At completion of the second treatment period, subjects will be asked whether they 
prefer the first drug they received or the second. A two-sample Wilcoxon paired difference test will be 
used for analysis.  
14.4.7  Randomization  
Randomization will be blocked so that after every 4 subjects, 2 will have been assigned initial treatment 
with G-CSF and 2 will ha ve been assigned initial treatment with plerixafor . 
15 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
15.1 Informed Consent Process 
Informed consent is a process where information is presented to enable persons to decide voluntarily whether or not to participate as a research subject. It is an on going conversation between the human 
research subject and the researchers, which begins before consent is given and continues until the end of 
the subject's involvement in the research. Discussions about the research will provide essential 
information about  the study and will include the purpose, duration,  experimental procedures, alternatives, 
and risks and benefits. Subjects will be given the opportunity to ask questions and have them answered.  
 Subjects will sign the informed consent documents prior to undergoing any research procedures. Subjects may wi thdraw consent at any time throughout the course of the study. A copy of the informed consent 
documents will be given to the subjects for their records. The researcher will document the signing of the consent forms in the subject’s medical record. The rights and welfare of the subjects will be protected by emphasizing to them that the quality of their medical care will not be adversely affected if they decline to participate in the study.  
 
The acquisition of main study informed consent will be documented i n the participant’s medical records, 
as required by 21 CFR 312.62. The informed consent form will be signed and personally dated by the 
participant and the person who conducted the consenting process. The original signed informed consent form will be retai ned in the subjects’ medical chart and a copy of it will be provided to them .  
 Consent from Non-English Speaking Participants  
If a non -English speaking participant is unexpectedly eligible for enrollment, the participant will be 
provided with the CC Short  Written Consent Form for Non-English Speaking Research Participants in the 
participant’s native language and a verbal explanation of the purpose, procedures and risks of the study as described MAS Policy M77 -2, NIH HRPP SOP 12 and 45 CFR 46.117(b)(2). The  IRB-approved English 
consent form will serve as basis for the verbal explanation of the study. The investigator will obtain an 
interpreter unless the investigator is fluent in the prospective participant’s language. Preferably, the 
interpreter will be som eone who is independent of the participant (i.e., not a family member). Interpreters 
provided by the CC will be used whenever possible. The interpreters will translate the IRB -approved 
English consent form verbatim and facilitate discussion between the participant and investigator.  
The IRB-approved English consent form will be signed by the investigator obtaining consent and a 
witness to the oral presentation. The CC Short Written Consent Form will be signed by the participant and a witness who observed th e presentation of information. The interpreter may sign the consent 
document as the witness and, in this case, will note “Interpreter” under the signature line. A copy of both signed forms will be provided to the participant to take home.  
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 62 of 74 
 
 The investigator  obtaining consent will document the consent process in the participant’s medical record, 
including the name of the interpreter. Further, all instances of use of the CC Short Written Consent Form will be reported to the IRB at the time of annual review. If  the CC Short Written Consent Form is used 
three times or more for the same language, this will be reported to the IRB immediately.  
15.2 Subject Confidentiality  
The investigator will ensure that the subjects’ anonymity is maintained. Subjects will not be identified in 
any publicly released reports of this study. All records will be kept confidential to the extent provided by 
federal, state, and local law. The study monitors and other authorized representatives of the sponsor may 
inspect all documents and records required to be maintained by the investigator, including, but not limited to, medical records. The investigator will inform the subjects that the above -named representatives will 
review their study -related records without violating their confidentiality. To maintain subject 
confidentiality, all laboratory specimens, evaluation forms, reports, and other records that leave the site 
will be identified only by a coded number to maintain subjects’ confidentiality. All records will be kept locked and all computer entry and networking programs will be done with coded numbers only. Clinical information will not be released without written permission of the subject, except as necessary for monitoring by IRB, FDA, NIAID, O HRP , or the sponsor’s designee.  
16 DATA HANDLING  AND RECORD KEEPING  
16.1 Data Management Responsibilities  
The investigator is responsible for assuring that the data collected is complete, accurate, and recorded in a timely manner. Source documentation (the point of initial recording of information) should support the data collected in the electronic data system , and must be signed and dated by the person recording and/or 
reviewing the data. All the data should be reviewed by the investigator and signed in ink or electronically .  
16.2 Data Capture Methods  
Study data will be collected at the study site and maintained in an electronic data system . These forms or 
systems are to be completed on an ongoing basis during the study. Only a uthorized individuals shall 
perform data ent ry into the electronic data system. Corrections to the electronic data system  shall be 
tracked electronically (password protected or through an audit trail) with the time, date, name of the individual making the correction, and details of the change being made.  
16.3 Types of Data  
Source documents include, but are not limited to, the subject’s medical records, laboratory reports, EKG tracings, x -rays, radiologist’s reports, subject’s diaries, biopsy reports, ultrasound photographs, progress 
notes, pharmacy records, and any other similar reports or records of procedures performed during the subject’s participation in the study  
16.4 Source Documents and Access to Source Data/Documents  
Study data will be collected and maintained in NIH-CC electronic records, and the subject’s study binder . 
The PI is responsible for assuring that the data collected are complete, accurate, and recorded in a timely 
manner. Source documentation (the point of initial recording of a piece of data) shoul d support the data 
collected, and must  be signed and dated by the person recording and/or reviewing the data. Source 
documents include all recordings of observations or notations of clinical activities and all reports and records necessary for the evaluation and reconstruction of the clinical trial. Source documents include, but 
are not limited to, the subject’s medical records, laboratory reports, progress notes, pharmacy records and any other similar reports or records of procedures performed during the subject’s participation in the 
study. Data from the  data s ystem will be collected directly from the subjects during study visits or will be 
abstracted from the subjects’ medical records. Each subject’s medical record must record his/her 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 63 of 74 
 
 participation in the clinical trial and study agent (with doses) and any other medical interventions or treatments administered, as well as any adverse reactions experienced during the trial.    
 
To maintain the subjects’ confidentiality, access to the data will be limited. Authorized representatives 
from NIAID and reg ulatory agencies will be permitted to examine clinical records for the purposes of 
quality assurance review, audits, and evaluation of the study safety and progress.  
16.5 Study Records Retention  
The investigator is responsible for retaining all essential documents listed in the ICH GCP guideline. Essential documentation for all the study subjects is to be maintained by the investigators in a secure 
storage facility for a minimum of 3 years according to NIAID policies.  The FDA requires study records to 
be retained for up to 2 years after marketing approval or disapproval (21 CFR 312.62), or until at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational agent 
for a specific indication. These records are also to be maintained in compliance with IRB, state, and federal medical records retention requirements, whichever is longest. All stored records are to be kept confidential to the extent required by federal, state, and local law.  
 Should the investigator wish to assign the study records to another party and/or move them to another 
location, the investigator must provide written notification of such intent to OCRPRO /NIAID, with the 
name of the person who will accept responsibility for the transferred records and/or their new location. Prior to the destruction or relocation of research records, NIAID must be notified in writing and written 
permission from OCRPRO /NIAID is required.  
  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 64 of 74 
 
 17 REFERENCES  
1. Kawai, T., and Malech, H.L. 2009. WHIM syndrome: congenital immune deficiency disease. Curr Opin Hematol  16:20- 26. 
2. McDermott, D.H., Lopez, J., Deng, F., Liu, Q., Ojode, T., Chen, H., Ulrick, J., Kwatemaa, N., Kelly, C., Anaya -O'Brien, S., Garofalo, M., Marquesen, M., Hilligoss, D., DeCastro, R., Malech, 
H.L., and Murphy, P.M. 2011. AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome. J Cell Mol Med  
15:2071-2081.  
3. McDermott, D.H., Liu, Q., Ulrick, J., Kwatemaa, N., Anaya -O'Brien, S., Penzak, S.R., Filho, 
J.O., Priel, D.A., Kelly, C., Garofalo, M., Littel, P., Marquesen, M.M., Hilligoss, D., Decastro, R., Fleisher, T.A., Kuhns, D.B., Malech, H.L., and Murphy, P.M. 2011. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood  118:4957-4962.  
4. Dale, D.C., Bolyard, A.A., Kelley, M.L., Westrup, E.C., Makaryan, V., Aprikyan, A., Wood, B., and Hsu, F.J. 2011. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, 
WHIM syndrome. Blood  118:4963-4966.  
5. McDermott, D.H., Liu, Q., Velez, D., Lopez, L., Anaya -O'Brien, S., Ulrick, J., Kwatemaa, N., 
Starling, J., Fleisher, T.A., Priel, D.A., et al. 2014. A phase 1 clinical trial of long -term, low -dose 
treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood  123:2308 -2316.  
6. Allen, S.J., Crown, S.E., and Handel, T.M. 2007. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol  25:787-820.  
7. Murphy, P.M. 2002. International Union of Pharmacology. XXX. Update on chemokine receptor 
nomenclature. Pharmaco l Rev  54:227-229.  
8. Zou, Y.R., Kottmann, A.H., Kuroda, M., Taniuchi, I., and Littman, D.R. 1998. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature  393:595-
599. 
9. Kawai, T., Choi, U., Cardwell, L., DeRavin, S.S., Naumann, N., Whiting -Theobald, N.L., Linton, 
G.F., Moon, J., Murphy, P.M., and Malech, H.L. 2007. WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C -terminus -trun cated CXCR4. Blood  109:78- 84. 
10. Hendrix, C.W., Collier, A.C., Lederman, M.M., Schols, D., Pollard, R.B., Brown, S., Jackson, 
J.B., Coombs, R.W., Glesby, M.J., Flexner, C.W., Bridger, G.J., Badel, K., MacFarland, R.T., 
Henson, G.W., and Calandra, G. 2004.  Safety, pharmacokinetics, and antiviral activity of 
AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic 
Syndr  37:1253-1262.  
11. Kawai, T., Choi, U., Whiting -Theobald, N.L., Linton, G.F., Brenner, S., Sechler, J.M., Murphy, 
P.M., and Malech, H.L. 2005. Enhanced function with decreased internalization of carboxy -
terminus truncated CXCR4 responsible for WHIM syndrome. Exp Hematol 33:460-468.  
12. Hernandez, P.A., Gorlin, R.J., Lukens, J.N., Taniuchi, S., Bohinjec, J., Francois, F., Klotman, M.E., and Diaz, G.A. 2003. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet  34:70-74.  
13. Diaz, G.A. 2005. CXCR4 mutations in WHIM syndrome: a misguided immune system? Immunol 
Rev 203:235-243.  
14. Orsini, M.J., Parent, J.L., Mundell, S.J., Marchese, A., and Benovic, J.L. 1999. Trafficking of the HIV coreceptor CXCR4. Role of arrestins and identification of residues in the c-terminal tail that mediate receptor internalization. J Biol Chem 274:31076-31086.  
15. Dotta, L., Tassone, L., and Badolato, R. 2011. Clinical and genetic features of Warts, 
Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome. Curr Mol Med  
11:317-325.  
16. Gulino, A.V., Moratto, D., Sozzani, S., Cavadini, P., Otero, K., Tassone, L., Imberti, L., 
Pirovano, S., Notarangelo, L.D., Soresina, R., Mazzolari, E., Nelson, D.L., and Badolato, R. 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 65 of 74 
 
 2004. Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. Blood 104:444- 452. 
17. Balabanian, K., Levoye, A., Klemm, L., Lagane, B., Hermine, O., Harriague, J., Baleux, F., 
Arenzana-S eisdedos, F., and Bachelerie, F. 2008. Leukocyte analysis from WHIM syndrome 
patients reveals a pivotal role for GRK3 in CXCR4 signaling. J Clin Invest  118:1074-1084.  
18. Balabanian, K., Brotin, E., Biajoux, V., Bouchet-Delbos, L., Lainey, E., Fenneteau, O., Bonnet, 
D., Fiette, L., Emilie, D., and Bachelerie, F. 2012. Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice. Blood 119:5722- 5730.  
19. Murphy, P.M., and McDermott, D.H. 2012. Unexpected developments in immune organs in WHIM syndrome. Blood  119:5610-5612.  
20. Mc Guire, P.J., Cunningham -Rundles, C., Ochs, H., and Diaz, G.A. 2010. Oligoclonality, 
impaired class switch and B-cell memory responses in WHIM syndrome. Clin Immunol  135:412-
421. 
21. Chae, K.M., Ertle, J.O., and Tharp, M.D. 2001. B -cell lymphoma in a patient with WHIM 
syndrome. J Am Acad Dermatol  44:124 -128.  
22. Imashuku, S., Miyagawa, A., Chiyonobu, T., Ishida, H., Yoshihara, T., Teramura, T., Kuriyama, K., Imamura, T., Hibi, S., Morimoto, A., and Todo, S. 2002. Epstein -Barr virus-associated T -
lymphoproliferative disease with hemophagocytic syndrome, followed by fatal intestinal B lymphoma in a young adult female with WHIM syndrome. Warts, hypogammaglobulinemia, 
infections, and myelo kathexis. Ann Hematol  81:470 -473.  
23. Badolato, R., Dotta, L., Tassone, L., Amendola, G., Porta, F., Locatelli, F., Notarangelo, L.D., 
Bertrand, Y., Bachelerie, F., and Donadieu, J. 2012. Tetralogy of fallot is an uncommon manifestation of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. J 
Pediatr  161:763-765.  
24. Dale, D.C., Bonilla, M.A., Davis, M.W., Nakanishi, A.M., Hammond, W.P., Kurtzberg, J., Wang, W., Jakubowski, A., Winton, E., Lalezari, P., and et al. 1993. A randomized contro lled phase III 
trial of recombinant human granulocyte colony -stimulating factor (filgrastim) for treatment of 
severe chronic neutropenia. Blood  81:2496-2502.  
25. Beaussant Cohen, S., Fenneteau, O., Plouvier, E., Rohrlich, P.S., Daltroff, G., Plantier, I., Dupuy, A., Kerob, D., Beaupain, B., Bordigoni, P., Fouyssac, F., Delezoide, A.L., Devouassoux, G., 
Nicolas, J.F., Bensaid, P., Bertrand, Y., Balabanian, K., Chantelot, C.B., Bachelerie, F., and 
Donadieu, J. 2012. Description and outcome of a cohort of 8 pa tients with WHIM syndrome from 
the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis 7:71.  
26. Calandra, G., Bridger, G., and Fricker, S. 2010. CXCR4 in clinical hematology. Curr Top Microbiol Immunol  341:173 -191.  
27. De Clercq, E. 2009. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol  77:1655- 1664.  
28. DiPersio, J.F., Micallef, I.N., Stiff, P.J., Bolwell, B.J., Maziarz, R.T., Jacobsen, E., Nademanee, A., McCarty, J., Br idger, G., and Calandra, G. 2009. Phase III prospective randomized double -
blind placebo-controlled trial of plerixafor plus granulocyte colony -stimulating factor compared 
with placebo plus granulocyte colony -stimulating factor for autologous stem -cell mobilization 
and transplantation for patients with non -Hodgkin's lymphoma. J Clin Oncol 27:4767- 4773.  
29. DiPersio, J.F., Stadtmauer, E.A., Nademanee, A., Micallef, I.N., Stiff, P.J., Kaufman, J.L., Maziarz, R.T., Hosing, C., Fruehauf, S., Horwitz, M., Cooper, D., Bridger, G., and Calandra, G. 
2009. plerixafor  and G -CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for 
autologous stem cell transplantation in patients with multiple myeloma. Blood  113:5720-5726.  
30. Lack, N.A., Green, B., Dale, D. C., Calandra, G.B., Lee, H., MacFarland, R.T., Badel, K., Liles, 
W.C., and Bridger, G. 2005. A pharmacokinetic -pharmacodynamic model for the mobilization of 
CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther  77:427-436.  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 66 of 74 
 
 31. Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S., Kitamura, Y., Yoshida, N., 
Kikutani, H., and Kishimoto, T. 1996. Defects of B -cell lymphopoiesis and bone -marrow 
myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature  382:635-638.  
32. Ma, Q., Jones, D., Borghesani, P.R., Segal, R.A., Nagasawa, T., Kishimoto, T., Bronson, R.T., 
and Springer, T.A. 1998. Impaired B -lymphopoiesis, myelopoiesis, and derailed cerebellar 
neuron migration in CXCR4- and SDF -1-deficient mice. Proc Natl Acad Sci U S A  95:9448- 9453.  
33. Gabrilove, J.L., Jakubowski, A., Fain, K., Grous, J., Scher, H., Sternberg, C., Yagoda, A., Clarkson, B., Bonilla, M.A., Oettgen, H.F., and et al. 1988. Phase I study of granulocyte colony -
stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest  
82:1454-1461.  
34. Morstyn, G., Campbell, L., Souza, L.M., Alton, N.K., Keech, J., Green, M., Sheridan, W., Metcalf, D., and Fox, R. 1988. Effect of granulocyte colony stimulating factor on neutropenia induce d by cytotoxic chemotherapy. Lancet 1:667-672.  
35. Bronchud, M.H., Scarffe, J.H., Thatcher, N., Crowther, D., Souza, L.M., Alton, N.K., Testa, 
N.G., and Dexter, T.M. 1987. Phase I/II study of recombinant human granulocyte colony -
stimulating factor in patie nts receiving intensive chemotherapy for small cell lung cancer. Br J 
Cancer 56:809-813.  
36. Rosenberg, P.S., Zeidler, C., Bolyard, A.A., Alter, B.P., Bonilla, M.A., Boxer, L.A., Dror, Y., 
Kinsey, S., Link, D.C., Newburger, P.E., Shimamura, A., Welte, K., and Dale, D.C. 2010. Stable 
long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G- CSF 
therapy. Br J Haematol  150:196- 199. 
37. Connelly, J.A., Choi, S.W., and Levine, J.E. 2012. Hematopoietic stem cell transplantation for 
severe congenital neutropenia. Curr Opin Hematol  19:44-51.  
38. Nagasawa, T., Nakajima, T., Tachibana, K., Iizasa, H., Bleul, C.C., Yoshie, O., Matsushima, K., 
Yoshida, N., Springer, T.A., and Kishimoto, T. 1996. Molecular cloning and characterization of a 
murine pre -B-cell growth -stimulating factor/stromal cell-derived factor 1 receptor, a murine 
homolog of the human immunodeficiency virus 1 entry coreceptor fusin. Proc Natl Acad Sci U S 
A 93:14726-14729.  
39. Vettenranta, K., Mottonen, M., and Riikonen, P. 2012. The use of plerixafor in harvesting 
autologous stem cells in the pediatric setting. Pediatr Blood Cancer  59:197-198.  
40. Aabideen, K., Anoop, P., Ethell, M.E., and Potter, M.N. 2011. The feasibility of plerixafor as a second -line stem cell mobilizing agent in children. J Pediatr Hematol Oncol  33:65-67.  
 
 
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
 
APPENDIX A: SCHED ULE OF PROCEDURES AND EVALUATION 
 
 
 
 
 
 
Evaluations  
Screening, Initial 
Evaluation Period and 
Baseline Assessments  
(Screening & Baseline)   
1 Pst
P Equilibration Period  
(Day Prior, Day 0, & Local Labs)   
 
1 Pst
P Year Treatment Period (52 
weeks)   
2 Pnd
P Equilibration 
& 2 Pnd
P Year 
Treatment Pa 
  
Reversion to  
Pre-study Treatment 
Screening 
V1 
W –(2 to 
20) Baseline 
V2 Prior  to 
Injection 
V3 
D -1/0 1 Pst
P Dose 
V3 
D 0 Local 
Labs Pa 
L 1, 2, 3  
W 2,  4, 6 
(± 7d) Evaluation 
V 4, 5, 6 
M 0, 4, 8 
(± 31d) Local 
Labs Pa 
L 4, 5, 6 
M 2, 6 , 10 
(± 31d) EOT 
V7 
M 12  
(± 
31d) 2 Pnd
P Study Drug Pb 
V 8-12 
L 7-12 
M13 to 26 
(± 31d)  
Local Labs Pa 
L 13-15 
W 2,  4 
(± 7d) 
M 28  
(± 31d) Study 
Completio
n 
V13 
M 30  
(± 61d) 
Informed consent  X           
Weight X  X   X  X X (x5)  
 X 
Vital Signs: Temp, Pulse, Blood Pressure X  X X Pc  X  X X (x6)  
 X 
Pregnancy testing  as applicable and 
contraception counseling as appropriate.  X  X   X  X X (x5)  
 X 
CBC with Differential X L X  L X L X X (x5) 
L (x6)   
L X 
ESR and Chemistry Pd X L X X L X L X X (x6)  
L X 
Vitamin B12, Folate   X       X X   
PT/PTT , Urinalysis, Viral Panel Pe
P     
X           
 
EKG   
X  
       
X  
X   
 
Echocardiogram (within 5 years)   
X           
History, Medications, Allergies, 
contraceptive counseling, and Physical 
Exam     
X   
X    
X  
  
X  
X (x4)   
X 
Review/adjust subject’s IVIg, 
prophylactic antibiotic and G- CSF dose   
X    
  
      
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 68 of 74 
 
  
Ultrasonogram of the spleen, DEXA Scan    
X       
X  
X   
Quantitative Immunoglob ulin and 
Leukocyte Phenotyping. Research blood 
as required.    
X  
X    
X   
X  
X (x5)   
X 
Antibody levels  
(Includes Tetanus, Diphtheria)   X      X X   
Photographs of cutaneous Warts  
(Photo of genital Warts is optional)    
X     
X  
  
X  
X (x4)   
X 
Standard Consults: Dermatology, Dental, 
GYN, ENT and Audiology    
X     
   
X  
X   
 
Additional Procedures/Consults if 
clinically indicated: PFT, chest- CT, 
sinus -CT, etc.    
X     
   
X  
X   
 
QOL (SF- 36v2) Questionnaire   X    X  X X (x4)   
Training/Review: Memory Aid , local 
labs, drug shipment, storage, and 
administration     X X        
  
Randomization   X          
G-CSF or plerixafor stopped at least 2 
days prior the 1 Pst
P day of injection    
X       
X  
X  
Optional: wart, skin, & bone marrow 
biopsies    
O     
O  
  
O  
O   
O 
Submission and review of subject 
Memory Aid   X X (x4) X (x26) X (x30)  
X (x10)  
AE monitoring   X X (x4) X (x26) X (x30)  
X (x10)  
V=visit; D=study Day; d= days; W=Study Week (from start of 1 Pst
P injection); M= Study Month; O=Optional; L= may be performed at subject’s Local facility; G- CSF=granulocyte colony stimulating factor;  
CBC=complete blood count; ESR; PT/PTT=prothrombin time/partial thromboplastin time; EKG=electrocardiogram; ENT=ear, nose, and throat; QOL=Quality of Life; AEs=ad verse events.  
Pa
PLocal Labs: Subjects may obtain their laboratory tests locally and the results sent to the NIH. If practical, provisions will be made for labs to be drawn at a Quest facility, at no cost, and accessible to the subject. ESR 
test is optional for local lab draws.  
Pb
P Column represents the summation and aggregate of the activities for the Equilibration and Treatment Period of the second (alternate) study drug.  
Pc
PIn addition to vital signs, orthostatic pulse and blood pressure should be measured prior to injection and 60 +/ - 20m post injection.  
Pd
PChemistry: NIH -Acute Care Panel, Hepatic Panel, Mineral Panel, Serum Protein, Lactate Dehydrogenase, Serum Uric Acid, & Creatine Kinase, and ESR. For home monitoring (local labs), BUN and creatinine are 
required.  Additional chemistries labs may be requested, and ESR if available may be requested.   
Pe
PThis includes HIV, hepatitis B/C.  HTLV type 1 and II.  
Pf
PSubjects will be instructed on how to record body temperature, fever, symptoms of infection, and anti- infective treatments/prophylaxis on a daily basis, and how to self -administer the study drugs.
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
 
APPENDIX B: FDA APPROVED PACKAGED INSERT: PLERIXAFOR  
 
Plerix afor (Mozobil ™) is an FDA approved product .  The approved package insert is considered a 
comprehensive source of safety data. The current version of the package insert is available on the 
Mozobil ™ website ( http://products.sanofi.us/Mozobil/mozobil.html).  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
 
APPENDIX C: FDA APPROVED PACKAGE INSERT: G- CSF  
 
G-CSF , Neupogen PTM 
P(filgrastim)  is an FDA-approved drug. T he approved package insert  is considered a 
comprehensive source of safety data. The current version of the package insert is available on the 
Neupogen PTM
P website ( 40Thttp://pi.amgen.com/united_states/neupogen/neupogen_pi_hcp_english.pdf 40T). 
 
  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 71 of 74 
 
 APPENDIX D: INFECTION SEVERITY SCORE (IS S) 
 
Type of Infection  Fever  Anti-Infective  Hospitalization  Total  
  0:  No chills/fever  0:  No Treatment  0:  No Hospitalization   
1:  Non-sterile site  1:  38.3 -39º C 1:  Topical  1:  Emergency Room   
2:  Sterile site  2:  > 39 º C 2:  Oral  2:  Hospital ized  
    3:  Parenteral  3:  ICU   
     
1 to 2  0 to 2  0 to 3  0 to 3  1 to 10  
 
 
These parameters will be used to develop a score for each infection.  Non-sterile site infections are those 
which occur in areas of the body routinely exposed to and colonized by microorganisms such as the oral cavity, bronchioles and upper respiratory tract, nasopharynx, vagina, GI tract, and skin; while, sterile sites 
would include th e lower respiratory tract, blood, muscle, bone, joints, urinary bladder, and other typically 
sterile locations.  Fever will refer to the maximum oral temperature recorded during the infection.  Anti-
infective treatment is scored based on the highest level of treatment i.e. intravenous antibiotic that is 
changed to oral would score a 3.  Similarly hospitalization will refer to the highest level of care received 
at any point during the infection.  Scores for each parameter will be added and thus the score for any given incidence of infection can range from 1-10.   
    
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 72 of 74 
 
 APPENDIX E: DOSING OF PLEXIFOR IN RENAL IMPAIRMENT  
 In subject s with moderate and severe renal impairment (estimated creatinine clearance [CrCl] ≤50 
mL/min), each dose of plerixafor ( Mozobil
PTM
P ) will be reduced b y one -third. Because of the renal 
excretion of the drug, this reduction in subjects with moderate and severe renal impairment is expected to 
result in similar drug levels compared with subjects with normal renal function.  
  
The following (Cockroft-Gault) formula may be used to estimate Creatinine Clearance (CrCl):   
 
Males:  
    Cr eatinine clearance (mL/min) = 17Tweight (kg) X (140 – age in years) 17T 
                                                        72 X serum creatinine (mg/dL)  
     
Females:  
    Creatinine clearance (mL/min) = 0.85 X value calculated for males  
 
Since there is insufficient information to make dosage recommendations in subject s on hemodialysis, 
subjects on dialysis or who have a CrCl <15 ml/min are excluded from this study.  
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
 
APPENDIX F: SAMPLE SUBJECT MEMORY AID  
Study Contact Information: Email and Phone # 
Date  
MM/DD/YY    Complete each question by circling ONE Answer from each row.  
Infection Related Treatments         
Drug 1  Route  Frequency  Yes   No    
Drug 2  Route  Frequency  Yes   No   
Additional Antibiotics:  Route:  Frequency:  No   Yes   
Study Drug and Side Effects        
Morning Injection  Batch ID   Site of Injection    No     
Evening Injection  Batch ID  Site of Injection    No     
Morning Injection Site Reaction  None    Tenderness  Pain  Ulceration  
Evening Injection Site Reaction  None    Tenderness  Pain  Ulceration  
Bone/Skeletal Pain (arms, legs, back)  None    Mild  Affects Function  Affects Self -care  
Pain (abdomen, shoulder etc.)  None    Mild  Affects Function  Affects Self -care  
Headache  None    Mild  Affects Function  Affects Self -care  
Dizziness  None    Unsteadiness  Affects Function  Affects Self -care  
Nausea  None    Loss of Appetite  Reduced Oral Intake  Tube Feeding  
Vomiting  None    1 to 2  3 to 5  6 or more  
Diarrhea  None    Increase 1 -4 stools  Increase 4 -6 stools  7 or more  
Additional Side Effect:  No   Mild  Affects Function  Affects Self -care  
Additional Side Effect:  No   Mild  Affects Function  Affects Self -care  
Fevers and Infections  (please inform study staff)        
Record your highest temp for the day  Enter Temp      
Missed School/Work due to side effect of s tudy drug  No   Partial Day  Full Day    
Missed School/Work because of Infection  No   Partial Day  Full Day    
Visits to the Doctor       
Visit to Doctor for Infection or Side Effects  No   Visit  to Doctor  Emergency Room  Hospital  
Treatment:  Route:  Frequency:  Taken    Not Taken    
Treatment:  Route:  Frequency:  Taken    Not Taken    
Please inform study staff of any events that are disabling or require immediate medical attention.  
Notes:         
          
        
        
        
Legend:         
Bolded Entries  Prefilled by NIH        
    Subject  selects 1 Item per row      
Italicized entries  Optional entries by subject      
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
 
 
APPENDIX G: EVALUATION OF INFECTION FORM  
 
Directions: Please circle relevant items and fill in underlined sections.  Use a different form for each 
infection unless contiguous and related.   
 
1) Date of Office or ER Visit, Hospitalization:_________________________  
 
2) Chief Complaint:_____________________________________________________  
 3) Date of Onset of Symptoms:_________________________________________  
 4) Diagnosis  (New / Chronic / Recurrent / Exacerbation) :  Otitis, Sinusitis, Dental Infection, Pharyngitis, 
Other oral infection, Bronchitis, Pneumonia, Cellulitis, Cutaneous abscess, Osteomyelitis, Endocarditis, Meningitis, Joint Infection, Gastroenteritis, urinary tract infection, unknown  
Other or further information:  ______________________________________  
 5) Site of Infection:____________________________________  
 6) Likely Cause of Infection: Viral, Bacterial, Fungal, Parasite, Unknown,  
 Other: ________________________________________       
 
7) Treatment Prescribed: __________________________________________________________  
 
8) Route of Treatment: Topical, Oral, intravenous  
 9) Length of Treatment Prescribed (days):_______________________________________  
 Relevant Laboratory Results:  10) Culture/Test Result: _____________________________________ pending or not performed.  
 11) Outcome of  Infection:  Pending, Unknown, Resolved, Resolved with residual symptoms, Ongoing,  
 Other:_____________________________  
 12) Additional Information (optional): ____________________________________________  
 